# EDGAR Filing Document

**Accession Number:** 0001109354
**File Stem:** 0000950170-25-103333
**Filing Date:** 2025-8
**Character Count:** 176563
**Document Hash:** 30bf901d7b22b580b2d0c95fbadeaa54
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-103333.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0000950170-25-103333

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 106

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRUKER CORP
- **CENTRAL INDEX KEY:** 0001109354
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 043110160
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30833
- **FILM NUMBER:** 251186680

**BUSINESS ADDRESS:**
- **STREET 1:** 40 MANNING RD
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821
- **BUSINESS PHONE:** 978663-3660

**MAIL ADDRESS:**
- **STREET 1:** 40 MANNING RD
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRUKER BIOSCIENCES CORP
- **DATE OF NAME CHANGE:** 20030721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRUKER DALTONICS INC
- **DATE OF NAME CHANGE:** 20000315

?xml version='1.0' encoding='ASCII'? 10-Q

[**<u>**Table of Contents**</u>**](#toc_page)

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

------

**Form** 10-Q

------

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934** 

**For the quarterly period ended** **June 30,** 2025

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934** 

**For the transition period from to** 

**Commission File Number** 000-30833

------

BRUKER CORPORATION

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| Delaware | 04-3110160 |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

40 Manning Road**,** Billerica**,** MA 01821

**(Address of principal executive offices) (Zip Code)** 

**Registrant's telephone number, including area code: (**978**)** 663-3660

------

**Securities registered pursuant to Section 12(b) of the Act:** 

---

| | | |
|:---|:---|:---|
| **Title of each class**<br>| &nbsp;&nbsp;&nbsp;**Trading**<br>**Symbols(s)**<br>| &nbsp;&nbsp;&nbsp;**Name of each exchange**<br>**on which registered**<br>|
| Common Stock | &nbsp;&nbsp;&nbsp;BRKR | &nbsp;&nbsp;&nbsp;Nasdaq Global Select Market |

---

------

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

---

| | |
|:---|:---|
| **Class**<br>| &nbsp;&nbsp;&nbsp;**Outstanding at July 29, 2025**<br>|
| **Common Stock, $0.01 par value per share** | **151,719,365 shares** |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**BRUKER CORPORATION** 

**Quarterly Report on Form 10-Q** 

**For the Quarter Ended June 30, 2025** 

**Table of Contents** 

---

| | | |
|:---|:---|:---|
|  |  | Page  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Part I** | [**<u>CONDENSED FINANCIAL INFORMATION</u>**](#part_i_financial_information) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 1: | [<u>Unaudited Condensed Consolidated Financial Statements</u>](#consolidated_financial_statements) | 3 |
|  | [<u>Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024</u>](#consolidated_balance_sheets) | 3 |
|  | [<u>Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024</u>](#consolidated_income_statement) | 4 |
|  | [<u>Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2025 and 2024</u>](#consolidated_comprehensive_income) | 5 |
|  | [<u>Unaudited Condensed Consolidated Statements of Redeemable Noncontrolling Interests and Shareholders' Equity for the three and six months ended June 30, 2025 and 2024</u>](#statements_of_equity) | 6 |
|  | [<u>Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024</u>](#consolidated_cash_flow) | 7 |
|  | [<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>](#notes_to_financia_statements) | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 2: | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#management_discussion_and_analysis) | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 3: | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#quantitative_and_qualitative_disclosures) | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 4: | [<u>Controls and Procedures</u>](#controls_and_procedures) | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Part II** | [**<u>OTHER INFORMATION</u>**](#part_ii_other_information) | 47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 1: | [<u>Legal Proceedings</u>](#legal_proceedings) | 47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 1A: | [<u>Risk Factors</u>](#risk_factors) | 47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 2: | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#unregistered_sales_of_equity_securities) | 47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 5: | [<u>Other Information</u>](#other_information) | 47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Item 6: | [<u>Exhibits</u>](#exhibits) | 48 |
|  | [<u>Signatures</u>](#signatures) | 49 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PART I FINANCIAL INFORMATION** 

**ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** 

**BRUKER CORPORATION**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS** 

**(in millions)** 

---

| | | |
|:---|:---|:---|
|  | **June 30,<br>2025** | **December 31,<br>2024** |
| &nbsp;&nbsp;**ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $92.0 | $183.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 522.6 | 565.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 1218.3 | 1067.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 329.8 | 236.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 2162.7 | 2053.2 |
| Property, plant and equipment, net | 758.5 | 669.3 |
| Goodwill and intangible assets, net | 2618.8 | 2419.8 |
| Other long-term assets | 799.8 | 664.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $6339.8 | $5806.7 |
| &nbsp;&nbsp;**LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt and finance lease obligations | $55.7 | $32.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 243.0 | 234.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue and customer advances | 478.1 | 438.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 570.6 | 576.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1347.4 | 1281.3 |
| Long-term debt | 2379.6 | 2061.8 |
| Other long-term liabilities | 746.0 | 648.4 |
| Redeemable noncontrolling interests | 47.4 | 18.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 1819.4 | 1797.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities, redeemable noncontrolling interests and shareholders' equity | $6339.8 | $5806.7 |

---

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

------

[**<u>**Table of Contents**</u>**](#toc_page)

**BRUKER CORPORATION** 

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** 

**(in millions, except per share data)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Product revenue | $634.7 | $654.4 | $1278.0 | $1241.3 |
| Service and other revenue | 162.7 | 146.3 | 320.8 | 281.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 797.4 | 800.7 | 1598.8 | 1522.4 |
| Cost of product revenue | 346.1 | 326.0 | 668.4 | 617.7 |
| Cost of service and other revenue | 93.4 | 90.1 | 181.3 | 167.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue | 439.5 | 416.1 | 849.7 | 785.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 357.9 | 384.6 | 749.1 | 737.4 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 231.4 | 221.3 | 456.8 | 416.6 |
| Research and development | 100.2 | 92.2 | 197.3 | 174.0 |
| Other charges, net | 14.4 | 23.0 | 51.3 | 33.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 346.0 | 336.5 | 705.4 | 624.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 11.9 | 48.1 | 43.7 | 112.9 |
| Interest and other income (expense), net | (11.4) | (24.2) | (18.1) | (17.4) |
| Income before income taxes, equity in income of<br> unconsolidated investees, net of tax, and noncontrolling <br> interests in consolidated subsidiaries | 0.5 | 23.9 | 25.6 | 95.5 |
| Income tax provision (benefit) | (3.1) | 16.1 | 5.6 | 35.9 |
| Equity in income (loss) of unconsolidated investees, net of tax | 0.6 | (0.2) | 1.0 |  |
| Consolidated net income | 4.2 | 7.6 | 21.0 | 59.6 |
| Net income (loss) attributable to noncontrolling interests in <br> consolidated subsidiaries | (3.4) |  | (4.0) | 1.1 |
| Net income attributable to Bruker Corporation | $7.6 | $7.6 | $25.0 | $58.5 |
| Net income per common share attributable to Bruker Corporation<br> shareholders: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.05 | $0.05 | $0.16 | $0.40 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.05 | $0.05 | $0.16 | $0.40 |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 151.6 | 147.4 | 151.6 | 146.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 151.7 | 148.0 | 151.8 | 147.0 |

---

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

------

[**<u>**Table of Contents**</u>**](#toc_page)

**BRUKER CORPORATION** 

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)** 

**(in millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;Consolidated net income | $4.2 | $7.6 | $21.0 | $59.6 |
| &nbsp;&nbsp;Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation gain (loss) before income taxes | 133.3 | (28.9) | 204.6 | (108.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense on foreign currency translation adjustments | 1.0 |  | 1.5 | (2.2) |
| &nbsp;&nbsp;Foreign currency translation gain (loss) after income taxes | 132.3 | (28.9) | 203.1 | (106.1) |
| &nbsp;&nbsp;Designated hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain (loss) on designated hedging instruments before income taxes | (195.7) | (9.8) | (246.4) | 71.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense related to designated hedging instruments | (46.8) | (2.3) | (58.9) | 16.8 |
| &nbsp;&nbsp;Gain (loss) on designated hedging instruments after income taxes | (148.9) | (7.5) | (187.5) | 54.6 |
| &nbsp;&nbsp;Pension and other postretirement plans: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total pension and other postretirement benefit liability adjustments gain (loss) before income taxes | (4.4) | (0.1) | (5.2) | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit related to total pension and other postretirement benefit liability adjustments | 0.9 |  | 1.1 |  |
| &nbsp;&nbsp;Total pension and other postretirement benefit liability adjustments gain (loss) after income taxes | (3.5) | (0.1) | (4.1) | 0.5 |
| Total other comprehensive income (loss) | (20.1) | (36.5) | 11.5 | (51.0) |
| Total Comprehensive income (loss) | (15.9) | (28.9) | 32.5 | 8.6 |
| Less: Comprehensive income (loss) attributable to noncontrolling interests | (0.3) | 0.2 |  | 1.3 |
| Less: Comprehensive income (loss) attributable to redeemable<br> noncontrolling interests | 0.8 | (0.4) | 1.0 | (1.2) |
| Total Comprehensive income (loss) attributable to Bruker Corporation | $(16.4) | $(28.7) | $31.5 | $8.5 |

---

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

------

[**<u>**Table of Contents**</u>**](#toc_page)

**BRUKER CORPORATION** 

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY** 

**(in millions, except share data)** 

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Redeemable<br>Noncontrolling<br>Interests** | **Number of Common<br>Shares Outstanding** | **Common<br>Stock<br>Amount** | **Number of Treasury<br>Shares** | **Treasury<br>Stock<br>Amount** | **Additional<br>Paid-In<br>Capital** | **Retained<br>Earnings** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss), net of tax** | **Total<br>Shareholders'<br>Equity<br>Attributable to<br>Bruker<br>Corporation** | **Noncontrolling<br>Interests in<br>Consolidated<br>Subsidiaries** | **Total<br>Shareholders'<br>Equity** |
| Balance at December 31, 2024 | $18.1 | 151677952 | $1.8 | 30778879 | $(1237.2) | $713.4 | $2406.7 | $(103.5) | $1781.2 | $15.9 | $1797.1 |
| Stock options exercised |  | 18771 |  |  |  | 0.4 |  |  | 0.4 |  | 0.4 |
| Restricted stock units vested |  | 24999 |  |  |  |  |  |  |  |  |  |
| Stock-based compensation |  |  |  |  |  | 5.2 |  |  | 5.2 |  | 5.2 |
| Employee stock purchase plan |  |  |  |  |  | 0.4 |  |  | 0.4 |  | 0.4 |
| Shares repurchased |  | (200731) |  | 200731 | (10.0) | (0.1) |  |  | (10.1) |  | (10.1) |
| Cash dividends paid to common shareholders <br>&nbsp;&nbsp;&nbsp;&nbsp;($0.05 per share) |  |  |  |  |  |  | (7.7) |  | (7.7) |  | (7.7) |
| Proceeds from the sale of (distributions to) noncontrolling interests, net |  |  |  |  |  |  |  |  |  | (0.5) | (0.5) |
| Consolidated net income (loss) | (0.4) |  |  |  |  |  | 17.4 |  | 17.4 | (0.3) | 17.1 |
| Other comprehensive income | 0.6 |  |  |  |  |  |  | 30.4 | 30.4 | 0.6 | 31.0 |
| Balance at March 31, 2025 | $18.3 | 151520991 | $1.8 | 30979610 | $(1247.2) | $719.3 | $2416.4 | $(73.1) | $1817.2 | $15.7 | $1832.9 |
| Stock options exercised |  | 87487 |  |  |  | 1.8 |  |  | 1.8 |  | 1.8 |
| Restricted stock units vested |  | 7334 |  |  |  | (0.1) |  |  | (0.1) |  | (0.1) |
| Stock-based compensation |  |  |  |  |  | 5.3 |  |  | 5.3 |  | 5.3 |
| Employee stock purchase plan |  | 100115 |  |  |  | 3.7 |  |  | 3.7 |  | 3.7 |
| Cash dividends paid to common shareholders <br>&nbsp;&nbsp;&nbsp;&nbsp;($0.05 per share) |  |  |  |  |  |  | (7.6) |  | (7.6) |  | (7.6) |
| Consolidated net income (loss) | (1.7) |  |  |  |  |  | 7.6 |  | 7.6 | (1.6) | 6.0 |
| Certain other acquisitions | 28.3 |  |  |  |  |  |  |  |  |  |  |
| Other comprehensive income (loss) | 2.5 |  |  |  |  |  |  | (23.9) | (23.9) | 1.3 | (22.6) |
| Balance at June 30, 2025 | $47.4 | 151715927 | $1.8 | 30979610 | $(1247.2) | $730.0 | $2416.4 | $(97.0) | $1804.0 | $15.4 | $1819.4 |

---

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Redeemable<br>Noncontrolling<br>Interests** | **Number of Common<br>Shares Outstanding** | **Common<br>Stock<br>Amount** | **Number of Treasury<br>Shares** | **Treasury<br>Stock<br>Amount** | **Additional<br>Paid-In<br>Capital** | **Retained<br>Earnings** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss), net of tax** | **Total<br>Shareholders'<br>Equity<br>Attributable to<br>Bruker<br>Corporation** | **Noncontrolling<br>Interests in<br>Consolidated<br>Subsidiaries** | **Total<br>Shareholders'<br>Equity** |
| Balance at December 31, 2023 | $18.7 | 145164826 | $1.7 | 30778879 | $(1237.2) | $282.9 | $2323.8 | $6.0 | $1377.2 | $17.4 | $1394.6 |
| Stock options exercised |  | 146765 |  |  |  | 3.4 |  |  | 3.4 |  | 3.4 |
| Restricted stock units vested |  | 23051 |  |  |  |  |  |  |  |  |  |
| Stock-based compensation |  |  |  |  |  | 4.6 |  |  | 4.6 |  | 4.6 |
| Employee stock purchase plan |  |  |  |  |  | 0.2 |  |  | 0.2 |  | 0.2 |
| Cash dividends paid to common shareholders <br>&nbsp;&nbsp;&nbsp;&nbsp;($0.05 per share) |  |  |  |  |  |  | (7.3) |  | (7.3) |  | (7.3) |
| Loans to noncontrolling interest |  |  |  |  |  |  |  |  |  | (0.9) | (0.9) |
| Consolidated net income (loss) | (0.3) |  |  |  |  |  | 50.9 |  | 50.9 | 1.4 | 52.3 |
| Other comprehensive loss | (0.5) |  |  |  |  |  |  | (13.7) | (13.7) | (0.3) | (14.0) |
| Balance at March 31, 2024 | $17.9 | 145334642 | $1.7 | 30778879 | $(1237.2) | $291.1 | $2367.4 | $(7.7) | $1415.3 | $17.6 | $1432.9 |
| Stock options exercised |  | 24484 |  |  |  | 0.5 |  |  | 0.5 |  | 0.5 |
| Restricted stock units vested |  | 1404 |  |  |  | (0.1) |  |  | (0.1) |  | (0.1) |
| Stock-based compensation |  |  |  |  |  | 4.8 |  |  | 4.8 |  | 4.8 |
| Employee stock purchase plan |  | 31291 |  |  |  | 2.1 |  |  | 2.1 |  | 2.1 |
| Public Offering, net of issuance costs of $0.8 million |  | 6000000 | 0.1 |  |  | 402.9 |  |  | 403.0 |  | 403.0 |
| Cash dividends paid to common shareholders <br>&nbsp;&nbsp;&nbsp;&nbsp;($0.05 per share) |  |  |  |  |  |  | (7.7) |  | (7.7) |  | (7.7) |
| Consolidated net income (loss) | (0.3) |  |  |  |  |  | 7.6 |  | 7.6 | 0.3 | 7.9 |
| Other comprehensive loss | (0.1) |  |  |  |  |  |  | (36.3) | (36.3) | (0.1) | (36.4) |
| Balance at June 30, 2024 | $17.5 | 151391821 | $1.8 | 30778879 | $(1237.2) | $701.3 | $2367.3 | $(44.0) | $1789.2 | $17.8 | $1807.0 |

---

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

------

[**<u>**Table of Contents**</u>**](#toc_page)

**BRUKER CORPORATION** 

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** 

**(in millions)** 

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** |
| <u>Cash flows from operating activities:</u> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated net income | $21.0 | $59.6 |
| &nbsp;&nbsp;Adjustments to reconcile net income to cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 106.5 | 79.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (38.6) | (22.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-cash expenses, net | (0.4) | 27.5 |
| &nbsp;&nbsp;Changes in operating assets and liabilities, net of acquisitions and divestitures: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable, net | (105.3) | (22.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other changes in operating assets and liabilities, net | (45.7) | (99.4) |
| Net cash provided by (used in) operating activities | (62.5) | 22.9 |
| <u>Cash flows from investing activities:</u> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (47.3) | (46.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for acquisitions, net of cash acquired | (69.5) | (1576.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other investing activities, net | (0.4) | (6.6) |
| Net cash used in investing activities | (117.2) | (1629.1) |
| <u>Cash flows from financing activities:</u> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of revolving line of credit | (219.1) | (840.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from revolving line of credit | 308.2 | 1073.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of long-term debt | (22.3) | (118.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from long-term debt | 2.9 | 805.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock, net | 5.3 | 408.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of dividends to common shareholders | (15.3) | (15.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (10.0) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other financing activities, net | (5.4) | (7.0) |
| Net cash provided by financing activities | 44.3 | 1307.5 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 44.9 | (19.7) |
| Net decrease in cash, cash equivalents and restricted cash | (90.5) | (318.4) |
| Cash, cash equivalents and restricted cash at beginning of period | 186.7 | 491.6 |
| Cash, cash equivalents and restricted cash at end of period | $96.2 | $173.2 |
| *Supplemental disclosure of cash flow information:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Cash paid for interest* | $35.5 | $21.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Cash paid for taxes* | $147.5 | $68.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Restricted cash period beginning balance* | $3.3 | $3.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Restricted cash period ending balance* | $4.2 | $3.5 |

---

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

------

[**<u>**Table of Contents**</u>**](#toc_page)

**BRUKER CORPORATION** 

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** 

**June 30, 2025** 

**1.** **Description of Business**

Bruker Corporation, together with its consolidated subsidiaries ("Bruker" or "the Company"), develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular, and cellular levels. Many of the Company's products are used to detect, measure, and visualize structural characteristics of chemical, biological, and industrial material samples.

The Company has four reportable segments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Bruker Scientific Instruments (BSI) BioSpin*:

Designs, manufactures, and distributes life science tools based on magnetic resonance technology, and provides automated laboratory research and development and quality control workflow solutions in a wide range of chemical research fields. Revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies, and nonprofit laboratories, as well as chemical, food and beverage, clinical, and other industrial companies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection*):

Designs, manufactures, and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies. Provides systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD and microbiology, and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Revenues are generated from academic institutions and medical schools; pharmaceutical, biotechnology, and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*BSI NANO*:

Designs, manufactures, and distributes advanced X-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable and mobile X-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, chip cytometry products and services for targeted spatial proteomics, multi-omic services, optofluidic and proteomic barcoding platforms, and products and services for spatial genomics research and spatial biology. Revenues are generated from academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies, and other businesses involved in materials research and life science research analysis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Bruker Energy & Supercon Technologies (BEST)*:

Develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and high energy physics research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. Revenues are generated from medical, clinical, pharmaceutical, and aerospace companies, as well as other businesses involved in materials research, fusion energy research, high energy physics, renewable energy, and environmental research. BEST also delivers extreme ultraviolet radiation (EUV/XUV) based technologies and solutions to world leading semiconductor companies and research labs.

The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of June 30, 2025, and December 31, 2024, and for the three and six months ended June 30, 2025, and 2024, have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated balance sheet data as of December 31, 2024 was derived from our audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2024 that was filed with the SEC on March 3, 2025. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement of the Company's financial position, results

------

[**<u>**Table of Contents**</u>**](#toc_page)

of operations, comprehensive income (loss), and cash flows have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.

At June 30, 2025, the Company's significant accounting policies, which are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, have not changed.

**2.** **Recent Accounting Pronouncements** 

In November 2024, the Financial Accounting Standards Board ("FASB") issued *ASU No. 2024-04 – Debt – Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments.* This new guidance clarifies the accounting treatment of whether the settlement of convertible debt should be accounted for as an induced conversion or extinguishment of convertible debt. This guidance is effective for annual reporting periods beginning after December 15, 2025. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

In November 2024, the FASB issued *ASU No. 2024-03 – Income Statement - Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

In December 2023, the FASB issued *ASU No. 2023-09 – Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires enhanced income tax disclosures, including disaggregation of information in the rate reconciliation table and disaggregation of information related to income taxes paid as presented on the Cash Flow Statement. This new guidance is effective for annual reporting periods beginning after December 15, 2024. The Company is evaluating the impact of this adoption on the consolidated financial statements and related disclosures.

**3.** **Acquisitions** 

During the three months ended June 30, 2025, and during the year ended December 31, 2024, the Company completed various acquisitions that collectively complement the product offerings of the Company's existing businesses.

The valuation methodology used to determine the fair value of the identifiable assets acquired and liabilities assumed, unless otherwise noted, is consistent with that described in *Note 2, Summary of Significant Accounting Policies* of the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***2025 Acquisitions***

The following table reflects the consideration transferred and the allocation to the identifiable assets acquired and liabilities assumed for the 2025 acquisitions (in millions):

---

| | | | |
|:---|:---|:---|:---|
| Acquisition (Segment) | **Recipe (CALID)** | **Other (Various)** | **Total** |
| Consideration Transferred: |  |  |  |
| Cash paid | $58.8 | $16.1 | $74.9 |
| Cash acquired | (5.2) | (1.3) | (6.5) |
| Fair value of redeemable noncontrolling interest | 27.2 | 1.1 | 28.3 |
| Working capital and other closing adjustments | 6.5 | 1.8 | 8.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consideration transferred, net of cash acquired | $87.3 | $17.7 | $105.0 |
| Allocation of Consideration Transferred: |  |  |  |
| Accounts receivable | $2.3 | $0.5 | $2.8 |
| Inventories | 7.7 | 0.5 | 8.2 |
| Other current assets | 0.1 | 0.4 | 0.5 |
| Property, plant and equipment | 21.2 | 0.7 | 21.9 |
| Other assets | 4.9 | 0.8 | 5.7 |
| Intangible assets: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | 14.0 | 6.7 | 20.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | 29.2 | 0.9 | 30.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade name | 1.6 | 0.9 | 2.5 |
| Goodwill | 35.0 | 14.0 | 49.0 |
| Deferred taxes (net) | (16.6) | (2.3) | (18.9) |
| Liabilities assumed | (12.1) | (5.4) | (17.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consideration allocated | $87.3 | $17.7 | $105.0 |

---

The table below summarizes information on the Recipe Chemicals + Instruments GmbH ("Recipe") acquisition:

---

| | |
|:---|:---|
|  | **Recipe** |
| Activity of acquired business | Provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical *in vitro* diagnostic kits for Liquid chromatography-mass spectrometry systems utilizing triple-quadrupole time-of flight mass spectrometry (LC-MS/MS), High Performance Liquid Chromatography (HPLC), and Inductively coupled plasma mass spectrometry (ICP-MS) assays. |
| Location | Munich, Germany |
| Acquired interest | 69.64% |
| Business acquired | Outstanding share capital of Recipe and Recipe's interest in their majority owned subsidiary, WoBau GmbH ("WoBau"). |
| Redeemable noncontrolling interest – other shareholders | The Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 30.36% for cash at a contractually defined redemption value exercisable beginning in 2029. The rights associated with the noncontrolling interests are contingently redeemable at the option of the Company or the noncontrolling interest holder. As redemption of the rights is contingently redeemable at the option of the noncontrolling interest holder, the Company classifies the carrying amount of these rights in the mezzanine section on the consolidated balance sheet, which is presented above the equity section and below liabilities. The redeemable noncontrolling interest is initially measured at fair value and subsequently at the greater of the amount that would be paid if the settlement occurred as of the balance sheet date based on the contractually defined redemption value and its carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. Adjustments to the carrying value of the redeemable noncontrolling interest are recorded through retained earnings. At the closing date the fair value of the redeemable noncontrolling interest was $27.2 million.<br>Additionally, the Company entered into an agreement with the noncontrolling interest holder of WoBau which provides the Company with the right to purchase the remaining 10.1% ownership interest of WoBau for cash at a price to be determined in the future, exercisable in 2029 or later. The rights associated with the noncontrolling interests are contingently redeemable at the option of the Company. At the closing date the fair value was determined to be de minimis. |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

Customer relationships and technology were the most significant identifiable intangible assets acquired. The fair value of the assets is estimated using a multi-period excess earnings method for customer relationships and a relief from royalty method for technology. The following table presents estimated useful life for the acquired intangible assets for the Recipe acquisition:

---

| | |
|:---|:---|
|  | **Recipe** |
| Intangible Asset — Technology | 10 years |
| Intangible Asset — Customer relationships | 15 years |
| Intangible Asset — Trade name | 1 year |

---

The amortization period for the intangible assets acquired for the Company's other acquisitions is five to twelve years for the technology.

The Company believes goodwill to represent future economic benefits of the acquisitions that are not individually identifiable, primarily expected synergies from combining the businesses such as the elimination of surplus facilities and headcount, and the utilization of the Company's existing commercial infrastructure to expand sales of the acquired businesses' products and services. The Company does not expect the amounts allocated to goodwill to be deductible for tax purposes.

The Company is in the process of finalizing the valuation of the assets acquired, inclusive of intangible assets, and liabilities assumed related to Recipe and certain other acquisitions which may result in adjustments to these assets and liabilities, including goodwill.

***Results of operations for 2025 acquired businesses***

Results from the acquisitions included in the consolidated financial statements of the Company from the acquisition dates through June 30, 2025 include revenues of $3.8 million and pre-tax losses totaling $0.8 million. The tax effect of pre-tax losses incurred will be included in the related jurisdictional tax returns of its subsidiaries.

***Supplemental Pro Forma Information for 2025 acquired businesses***

The consolidated results for the three and six months ended June 30, 2025 would not be materially different had the 2025 acquisitions been completed on January 1, 2025. As such, additional pro forma information combining the results of operations of the Company and these acquisitions have not been included in these consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***2024 Acquisitions***

The following table reflects the consideration transferred and the allocation to the identifiable assets acquired and liabilities assumed for the 2024 acquisitions (in millions):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **NanoString Technologies** | **ELITechGroup** | **Chemspeed Technologies** | **Other** | **Total** |
| Consideration Transferred: |  |  |  |  |  |
| Cash paid | $392.6 | $951.9 | $175.4 | $128.9 | $1648.8 |
| Cash acquired | (0.5) | (43.4) | (0.6) | (8.1) | (52.6) |
| Fair value of contingent consideration |  |  |  | 13.4 | 13.4 |
| Working capital and other closing adjustments |  | 22.7 |  | 3.5 | 26.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consideration transferred, net of cash acquired | $392.1 | $931.2 | $174.8 | $137.7 | $1635.8 |
| Allocation of Consideration Transferred: |  |  |  |  |  |
| Accounts receivable | $16.8 | $30.6 | $7.0 | $3.9 | $58.3 |
| Inventories | 38.8 | 31.6 | 46.6 | 31.2 | 148.2 |
| Other current assets | 8.9 | 15.7 | 1.4 | 3.1 | 29.1 |
| Property, plant and equipment | 31.0 | 36.2 | 1.8 | 1.4 | 70.4 |
| Other assets | 23.1 | 41.3 | 17.3 | 9.7 | 91.4 |
| Intangible assets: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | 54.0 | 193.3 | 27.9 | 42.6 | 317.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | 38.0 | 236.3 | 51.5 | 8.5 | 334.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Backlog |  | 0.5 | 9.4 | 4.9 | 14.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade name | 14.0 | 12.3 | 4.8 | 3.1 | 34.2 |
| Goodwill | 253.5 | 501.1 | 127.8 | 75.6 | 958.0 |
| Deferred taxes (net) | 4.8 | (100.8) | (14.0) | (3.2) | (113.2) |
| Liabilities assumed | (90.8) | (66.9) | (106.7) | (43.1) | (307.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consideration allocated | $392.1 | $931.2 | $174.8 | $137.7 | $1635.8 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Acquisitions material to the Company's financial statements***

The table below summarizes information on acquisitions material to the Company's financial statements in 2024:

---

| | | | |
|:---|:---|:---|:---|
|  | **NanoString Technologies** | **ELITechGroup** | **Chemspeed Technologies** |
| Acquisition date | May 6, 2024 | April 30, 2024 | March 6, 2024 |
| Bruker segment | BSI NANO | BSI CALID | BSI BBIO |
| Activity of acquired business | End-to-end research solutions in the spatial biology field and provides life-science research solutions for spatial transcriptomics and gene expression analysis which have been critical in enabling scientists and medical researchers to advance vital discovery, translational, and pre-clinical disease research. The acquisition complements the Company's spatial proteomics platform and contributes to further its leadership in the post-genomic era. | Molecular diagnostics, microbiology and biomedical testing equipment. The acquisition expands the segment's portfolio with the addition of pioneering innovation in molecular diagnostics which combined with the Segment's existing offerings establish Bruker as an innovative and growing infectious disease specialist in the in-vitro diagnostics market. | Automated laboratory research and development and quality control workflow solutions in a wide range of chemical research fields. The acquisition expands the segment's portfolio in vendor-agnostic scientific software, R&D, and laboratory automation. |
| Location | Washington, U.S.A. | Various - Primarily Torino, Italy and Washington and Utah, U.S.A. | Füllinsdorf, Switzerland |
| Acquired interest | 100% | 100% | 100% |
| Business/technology acquired | Substantially all of the assets and rights associated with the business of NanoString Technologies, Inc. including the equity interests of the six subsidiaries (collectively, "NanoString"). The Company also assumed certain of its liabilities, including potential liabilities associated with ongoing litigations. Included in the liabilities assumed as of the acquisition date is $44.7 million determined in accordance with ASC Topic 450. Refer to Note 20, Commitments and Contingencies for more details on these litigations. | Outstanding share capital of TecInvest S.à r.l, Eliman 1 S.à r.l, and Eliman 2 S.à r.l, and their 100% interests in 18 subsidiaries (collectively "ELITech" or "ELITech Group"). | Outstanding share capital of Chemspeed Technologies AG and its three wholly owned subsidiaries (collectively "Chemspeed"). |

---

In the acquisitions above, customer relationships and technology intangible assets were the most significant identifiable assets acquired. The fair value of the intangible assets is estimated using a multi-period excess earnings method for customer relationships and a relief from royalty method for technology. For the acquisition of ELITechGroup, the cash flow projections for the customer relationships included significant judgments and assumptions related to customer attrition rates, contributory asset charges, and discount rates and the cash flow projections for the technology included significant judgments and assumptions related to revenue growth rates, royalty rates, obsolescence rates, and discount rates.

The following table presents estimated useful life for the acquired intangible assets as determined by the Company:

---

| | | | |
|:---|:---|:---|:---|
|  | **NanoString Technologies** | **ELITechGroup** | **Chemspeed Technologies (a)** |
| Intangible Asset — Technology | 12 years | 4 to 14 years | 7 years |
| Intangible Asset — Tradenames | 12 years | 6 years | 10 years |
| Intangible Asset — Customer relationships | 15 years | 5 to 15 years | 15 years |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) The Company expects to amortize backlog through the first quarter of 2026.*

The Company believes goodwill to represent future economic benefits of the acquisitions that are not individually identifiable, primarily expected synergies from combining the businesses such as the elimination of surplus facilities and headcount, and the utilization of the Company's existing commercial infrastructure to expand sales of the acquired businesses' products and services. The Company does not expect the amounts allocated to goodwill for ELITechGroup or Chemspeed to be deductible for tax purposes. The Company expects the amounts allocated to goodwill for NanoString to be deductible for tax purposes.

In the first quarter of 2025, the Company finalized its determination of the fair value of the identifiable assets acquired and liabilities assumed for the Chemspeed acquisition. In the second quarter of 2025, the Company finalized its determination of the fair

------

[**<u>**Table of Contents**</u>**](#toc_page)

value of the identifiable assets acquired and liabilities assumed for the NanoString and ELITechGroup acquisitions with no further adjustments in addition to the immaterial adjustments recorded in prior quarters.

***Other 2024 Acquisitions***

During the year ended December 31, 2024, the Company acquired other businesses which were accounted for under the acquisition method that complemented the Company's existing product offerings.

The following table reflects the consideration transferred and the respective reportable segment for the acquisitions (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of Acquisition** | **Date Acquired** | **Segment** | **Total<br>Consideration, net of Cash Acquired** | **Cash<br>Consideration** |
| Nion, LLC | January 2, 2024 | BSI NANO | $42.9 | $37.4 |
| Spectral Instruments Imaging LLC | February 1, 2024 | BSI BBIO | 28.8 | 29.0 |
| Other (In aggregate) | Various | Various | 66.0 | 62.5 |
|  |  |  | $137.7 | $128.9 |

---

For the period from the date of acquisition through December 31, 2024, the revenues and results of operations included in the consolidated financial statements of the Company from the other acquisitions listed in table above were not material, therefore, additional pro forma information combining the results of operations of the Company and these acquisitions have not been included.

The table below summarizes information on certain of the Company's other acquisitions in 2024:

---

| | | |
|:---|:---|:---|
|  | **Nion, LLC** | **Spectral Instruments Imaging LLC** |
| Activity of acquired business | Designer and manufacturer of high-end electron-optical instruments with diverse applications to the needs of its customers. | Manufacturer of preclinical optical systems for bioluminescent, fluorescent and x-ray imaging to fit the workflows of animal scientists. |
| Location | Washington, U.S.A. | Arizona, U.S.A. |
| Acquired interest | 100% | 100% |
| Business/technology acquired | Outstanding share capital of Nion, LLC ("Nion"). | Outstanding share capital of Spectral Instruments Imaging, LLC ("Spectral"). |
| Contingent consideration | Cash consideration is subject to adjustments of up to $23.0 million if certain revenue and non-revenue milestones are achieved through 2026. | Cash consideration is subject to adjustments of up to $10.0 million if certain revenue and EBITDA targets are met through 2025. |

---

The following table presents estimated useful life for the acquired intangible assets for the material other acquisitions in 2024 as determined by the Company:

---

| | | |
|:---|:---|:---|
|  | **Nion, LLC (a)** | **Spectral Instruments Imaging LLC** |
| Intangible Asset — Technology | 7 years | 6 years |
| Intangible Asset — Tradenames | 7 years | not applicable |
| Intangible Asset — Customer relationships | 15 years | 14 years |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) The Company expects to amortize backlog through the fourth quarter of 2027.*

The amortization period for the intangible assets acquired for the Company's other acquisitions is seven to eleven years for the technology, eleven to fifteen for customer relationships and twelve years for tradenames. The fair values of the trade name and technology of certain acquisitions were not material and were expensed in full during 2024.

The Company believes goodwill to represent future economic benefits of the acquisitions that are not individually identifiable, primarily expected synergies from combining the businesses such as the elimination of surplus facilities and headcount, and the utilization of the Company's existing commercial infrastructure to expand sales of the acquired businesses' products and services. The Company does not expect the amounts allocated to goodwill to be deductible for tax purposes.

The Company has finalized its valuation of the assets acquired and liabilities assumed related to the Spectral Instruments Imaging LLC and Nion, LLC acquisitions within the measurement period, and no further material adjustments were be made.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Results of operations for 2024 acquired businesses***

Results from the acquisitions included in the consolidated financial statements of the Company from the acquisition dates through December 31, 2024 include revenues of $259.5 million and pre-tax losses totaling $108.0 million. Pre-tax losses include purchased intangible amortization and step up inventory costs related to the acquisitions as well as acquisition-related expenses, which are recorded within Other charges, net in the consolidated statements of operations. Acquisition-related expenses primarily relate to pre-close services, legal and professional services associated with integration activities, and other transaction costs. The tax effect of pre-tax losses incurred will be included in the related jurisdictional tax returns of its subsidiaries.

***Supplemental Pro Forma Information*** 

The unaudited pro forma financial information in the table below summarizes the combined GAAP revenue and net income (loss) results of the Company as though the material acquisitions of ELITechGroup and Chemspeed had been completed on January 1, 2024 (in millions):

---

| | | | |
|:---|:---|:---|:---|
|  | **Year ended <br>December 31, 2024** | **Year ended <br>December 31, 2024** | **Year ended <br>December 31, 2024** |
|  | **Before Adjustments** | **Pro forma<br>Adjustments** | **After Adjustments** |
| Revenue | $3426.0 | $— | $3426.0 |
| Net income (loss) | $115.3 | $(15.7) | $99.6 |

---

The revenue and net income (loss) results for all 2024 acquisitions are included in the consolidated financial statements for the three and six months ended, June 30, 2025.

NanoString was unable to file its Annual Report on Form 10-K for the year ended December 31, 2023, under the Securities and Exchange Act of 1934, as amended, following NanoString and certain of its subsidiaries filing voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware on February 4, 2024. Further, management considers that results of NanoString for the period from October 1, 2023, through May 6, 2024, are unlikely to be meaningful to users of these financial statements given the operations and financial results of NanoString were inherently materially impacted by the bankruptcy declaration. Accordingly, the pro forma financial information does not include the results of NanoString from January 1, 2024, through its acquisition date of May 6, 2024, as the historical financial statements after the quarter ended September 30, 2023 are not meaningful.

The pro forma adjustments include the following (in millions):

---

| | |
|:---|:---|
|  | **December 31, 2024** |
| Net increase in amortization and depreciation expense associated with tangible and intangible assets | $(2.4) |
| Net increase in interest expense | (13.3) |
| Total pro forma adjustments - net loss | $(15.7) |

---

The supplemental pro forma financial information presented above is for illustrative purposes only and does not include the pro forma adjustments that would be required under Article 11 of Regulation S-X for pro forma financial information. This supplemental pro forma financial information is not necessarily indicative of the financial position or results of operations that would have been realized if the NanoString, ELITechGroup, and Chemspeed acquisitions had been completed on January 1, 2024. No effect has been given for synergies, if any, that may have been achieved through the acquisitions nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that the Company believes are reasonable under the circumstances.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**4.** **Minority and Equity-method Investments**

***2025*** 

As of June 30, 2025, the aggregate amount of equity investments without readily determinable fair value using the measurement alternative is $38.7 million. During the six months ended June 30, 2025, the Company completed four minority investments. The following table reflects the consideration transferred (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Financial<br>Statement<br>Classification** | **Date Acquired** | **Total<br>Consideration** | **Cash<br>Consideration** |
| Other minority investments | Other long-term assets | Various | $3.9 | $3.2 |
|  |  |  | $3.9 | $3.2 |

---

***2024***

As of December 31, 2024, the aggregate amount of equity investments without a readily determinable fair value using the measurement alternative was $35.6 million. During the year ended December 31, 2024, the Company completed several minority investments. The following table reflects the consideration transferred (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Financial<br>Statement<br>Classification** | **Date Acquired** | **Total<br>Consideration** | **Cash<br>Consideration** |
| NovAliX | Other long-term assets | July 31, 2024 | $50.1 | $34.1 |
| Other minority investments | Other long-term assets | Various | 14.2 | 14.2 |
|  |  |  | $64.3 | $48.3 |

---

On July 31, 2024, the Company acquired a minority equity interest in NovAliX a preclinical contract research organization specializing in expert drug discovery services, headquartered in Strasbourg, France. The Company obtained a 30% interest in NovAliX's common stock in exchange for consideration of EUR 31.5 million (approximately $34.1 million). The Company accounts for its investment in NovAliX using the equity-method of accounting. Concurrent with the transaction, the Company entered into an agreement with the remaining shareholders that provides the Company with the right to purchase, and the shareholders with the right to sell, the remaining ownership of NovAliX for cash at a contractually defined redemption value exercisable beginning in 2029 and ending in 2034. The Company recognized a liability, classified in other long-term liabilities in the consolidated balance sheet, related to the potential obligation to acquire the remaining equity interests if the purchase option is exercised, estimated at EUR 14.4 million (approximately $16.0 million) using the discounted cash flow method.

Refer to *Note 11, Interest and other income (expense), net*, for information on impairment charges, to write down the carrying value of certain minority investments for the three and six months ended June 30, 2025 and 2024, respectively.

**5.** **Goodwill and Intangible Assets** 

***Goodwill*** 

The following table sets forth the changes in the carrying amount of goodwill (in millions):

---

| | |
|:---|:---|
| Balance at December 31, 2024 | $1507.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period additions | 49.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period adjustments | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency effect | 92.7 |
| Balance at June 30, 2025 | $1649.2 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Intangible Assets*** 

The following is a summary of intangible assets (in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Gross<br>Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net Carrying<br>Amount** | **Gross<br>Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net Carrying<br>Amount** |
| Existing technology and related patents | $798.4 | $(338.9) | $459.5 | $724.5 | $(291.3) | $433.2 |
| Customer relationships | 613.9 | (155.8) | 458.1 | 550.6 | (125.6) | 425.0 |
| Trade names | 66.7 | (21.9) | 44.8 | 60.9 | (16.1) | 44.8 |
| Other | 18.2 | (11.0) | 7.2 | 16.5 | (7.0) | 9.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets | $1497.2 | $(527.6) | $969.6 | $1352.5 | $(440.0) | $912.5 |

---

For the three months ended June 30, 2025, and 2024, the Company recorded amortization expense of $31.5 million and $25.1 million, respectively, related to intangible assets subject to amortization. For the six months ended June 30, 2025, and 2024, the Company recorded amortization expense of $58.8 million and $41.3 million, respectively, related to intangible assets subject to amortization.

On a quarterly basis, the Company reviews its goodwill and intangible assets to determine if there have been any triggering events that could indicate an impairment. Impairment losses are recorded when indicators of impairment are present and the quoted market price, if available or the estimated fair value of those assets are less than the assets' carrying value, and are not recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. Based on the results of these analyses, during the three and six months ended June 30, 2025, the Company recognized impairment charges of $6.8 million and $7.2 million respectively, to write off certain intangible assets. There were no such intangible assets impairment charges recorded during the three and six months ended June 30, 2024.

Current macroeconomic conditions and uncertainties, including inflationary pressures, changes to trade and tariff policies, customs duties imposed or that may be imposed by the new presidential administration in the U.S., geopolitical tensions and possible expansion of current conflicts, and increasing potential of conflict involving countries in Asia that are significant to the Company's supply chain operations, such as Taiwan and China, could adversely impact the fair value of our reporting units and cause the Company to consider whether goodwill, intangible assets, and other long-lived assets may require an impairment assessment. The Company continues to monitor its goodwill, intangible assets, and other long-lived assets for impairment and additional charges may be recorded in the future from these analyses depending on market conditions and actual and forecasted future results.

**6.** **Revenue** 

The following table presents the Company's revenues by end customer geography for the periods reported (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| United States | $222.9 | $243.7 | $440.3 | $438.5 |
| Germany | 59.1 | 83.5 | 120.2 | 150.3 |
| Europe excluding Germany | 213.4 | 192.3 | 437.5 | 370.4 |
| China | 114.7 | 120.4 | 215.9 | 236.1 |
| Asia Pacific excluding China | 127.4 | 106.2 | 258.8 | 213.2 |
| Other | 59.9 | 54.6 | 126.1 | 113.9 |
| &nbsp;&nbsp;Total revenue | $797.4 | $800.7 | $1598.8 | $1522.4 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

The following table presents revenue for the Company recognized at a point in time versus over time for the periods reported (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue recognized at a point in time | $675.1 | $686.5 | $1353.8 | $1295.0 |
| Revenue recognized over time | 122.3 | 114.2 | 245.0 | 227.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $797.4 | $800.7 | $1598.8 | $1522.4 |

---

As of June 30, 2025 and December 31, 2024 the following balances were associated with revenue (in millions):

---

| | | |
|:---|:---|:---|
|  | **June 30,<br>2025** | **December 31,<br>2024** |
| Contract assets | $127.1 | $105.2 |
| Contract liabilities (a) | 584.1 | 538.2 |
| Remaining performance obligations (b) | $2109.1 | $2090.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Approximately $232.5 million of the contract liability balance on December 31, 2024, was recognized as revenue during the six months ended June 30, 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*b) Bruker's mix of remaining performance obligations consist of firm orders under non-cancelable purchase orders received from customers and the timing of revenue recognition can vary significantly due to a variety of factors. Bruker manufactures innovative scientific instruments and diagnostic solutions which can result in varying production and installation timing due to components, customization, manufacturing, assembly, testing processes, and customer site availability or readiness. Bruker's expected completion of performance obligations can vary from year to year based on these and other factors. As a result, performance obligations on any particular date may be indicative of Bruker's short-term revenue performance but is not necessarily a reliable indicator of long-term revenue performance. The Company will recognize revenues for these performance obligations as they are satisfied, the majority of which is expected to occur within the next twelve months.* 

***Lease Revenue*** 

The Company's right to future consideration from reagent purchases under the reagent agreements is allocated to instrument revenue and is recorded as a lease receivable within other current and long-term assets. Agreements that do not meet the criteria to be classified as a sales-type lease are classified as operating leases. Lease revenue is presented in product revenue in the consolidated statements of operations and consisted of less than 2% of total consolidated revenue in each of the three and six months ended June 30, 2025 and 2024, respectively.

**7.** **Business Segment Information**

The Company's CEO is the chief operating decision maker. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. We exclude from segment expenses and segment operating income (loss) certain corporate-related expenses and certain transactions or adjustments, such as costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, and costs associated with our global information technology transition initiatives. The Company's intersegment sales and transfers are accounted for at discounted market-based prices based on intersegment agreements. The chief operating decision maker uses segment operating income (loss) to assess the performance for each segment by comparing the results of each segment with one another, comparing actual results to budget and prior year, as well as to allocate resources.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The following tables present segment results for the three and six months ended June 30, 2025, and 2024 (in millions):

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30, 2025** | **Three Months Ended<br>June 30, 2025** | **Three Months Ended<br>June 30, 2025** | **Three Months Ended<br>June 30, 2025** | **Three Months Ended<br>June 30, 2025** | **Three Months Ended<br>June 30, 2024** | **Three Months Ended<br>June 30, 2024** | **Three Months Ended<br>June 30, 2024** | **Three Months Ended<br>June 30, 2024** | **Three Months Ended<br>June 30, 2024** |
|  | **BSI BioSpin** | **BSI CALID** | **BSI NANO** | **BEST** | **Total** | **BSI BioSpin** | **BSI CALID** | **BSI NANO** | **BEST** | **Total** |
| Revenue from external customers | $195.3 | $285.8 | $252.1 | $64.2 | $797.4 | $217.5 | $265.6 | $252.5 | $65.1 | $800.7 |
| Intersegment revenue |  |  |  | 2.1 | 2.1 |  |  |  | 4.0 | 4.0 |
| Total segment revenue | $195.3 | $285.8 | $252.1 | $66.3 | $799.5 | $217.5 | $265.6 | $252.5 | $69.1 | $804.7 |
| Segment expenses: |  |  |  |  |  |  |  |  |  |  |
| Cost of revenue | $108.1 | $125.6 | $125.6 | $52.3 | $411.6 | $110.8 | $111.5 | $119.8 | $52.0 | $394.1 |
| Selling, general and administrative | 40.9 | 76.9 | 72.7 | 5.7 | 196.2 | 38.3 | 68.9 | 71.8 | 5.2 | 184.2 |
| Research and development | 23.2 | 30.0 | 44.4 | 1.1 | 98.7 | 21.8 | 26.8 | 41.7 | 1.3 | 91.6 |
| Segment operating income | $23.1 | $53.3 | $9.4 | $7.2 | $93.0 | $46.6 | $58.4 | $19.2 | $10.6 | $134.8 |
| *Reconciliation of Total operating income:* |  |  |  |  |  |  |  |  |  |  |
| Corporate, elimination and other (a) |  |  |  |  | $21.1 |  |  |  |  | $24.3 |
| Unallocated expenses (b) |  |  |  |  | 60.0 |  |  |  |  | 62.4 |
| Total consolidated operating income |  |  |  |  | $11.9 |  |  |  |  | $48.1 |
| Interest and other income (expense), net |  |  |  |  | (11.4) |  |  |  |  | (24.2) |
| Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  |  |  | $0.5 |  |  |  |  | $23.9 |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Six Months Ended<br>June 30, 2025** | **Six Months Ended<br>June 30, 2025** | **Six Months Ended<br>June 30, 2025** | **Six Months Ended<br>June 30, 2025** | **Six Months Ended<br>June 30, 2025** | **Six Months Ended<br>June 30, 2024** | **Six Months Ended<br>June 30, 2024** | **Six Months Ended<br>June 30, 2024** | **Six Months Ended<br>June 30, 2024** | **Six Months Ended<br>June 30, 2024** |
|  | **BSI BioSpin** | **BSI CALID** | **BSI NANO** | **BEST** | **Total** | **BSI BioSpin** | **BSI CALID** | **BSI NANO** | **BEST** | **Total** |
| Revenue from external customers | $403.1 | $565.9 | $508.7 | $121.1 | $1598.8 | $400.3 | $493.5 | $492.9 | $135.7 | $1522.4 |
| Intersegment revenue |  |  |  | 4.5 | 4.5 |  |  |  | 6.5 | 6.5 |
| Total segment revenue | $403.1 | $565.9 | $508.7 | $125.6 | $1603.3 | $400.3 | $493.5 | $492.9 | $142.2 | $1528.9 |
| Segment expenses: |  |  |  |  |  |  |  |  |  |  |
| Cost of revenue | $217.8 | $243.4 | $244.4 | $98.7 | $804.4 | $199.9 | $205.3 | $233.8 | $110.5 | $749.5 |
| Selling, general and administrative | 79.9 | 149.8 | 142.1 | 11.0 | 382.8 | 75.3 | 126.7 | 134.8 | 10.9 | 347.7 |
| Research and development | 45.2 | 58.0 | 89.6 | 1.7 | 194.5 | 43.9 | 52.0 | 75.3 | 2.0 | 173.2 |
| Segment operating income | $60.2 | $114.7 | $32.6 | $14.2 | $221.6 | $81.2 | $109.5 | $49.0 | $18.8 | $258.5 |
| *Reconciliation of Total operating income:* |  |  |  |  |  |  |  |  |  |  |
| Corporate, elimination and other (a) |  |  |  |  | $47.9 |  |  |  |  | $47.2 |
| Unallocated expenses (b) |  |  |  |  | 130.0 |  |  |  |  | 98.4 |
| Total consolidated operating income |  |  |  |  | $43.7 |  |  |  |  | $112.9 |
| Interest and other income (expense), net |  |  |  |  | (18.1) |  |  |  |  | (17.4) |
| Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries |  |  |  |  | $25.6 |  |  |  |  | $95.5 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Represents corporate costs and intersegment eliminations not allocated to the reportable segments. Unallocated costs include general and administrative expenses not directly incurred by the segments such as professional fees incurred for the quarterly reviews and annual audit of the consolidated financial statements, personnel costs of corporate accounting, finance, legal, and IT resources, and other expense items.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*b) Unallocated expenses consist of costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets, costs associated with our global information technology transition initiatives, and other costs.*

------

[**<u>**Table of Contents**</u>**](#toc_page)

Refer to *Note 6, Revenue* for information on revenue by geographical area.

Total capital expenditures and depreciation and amortization by segment are as follows for the periods reported (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Capital Expenditures: |  |  |  |  |
| BSI BioSpin | $2.3 | $3.8 | $5.5 | $3.4 |
| BSI CALID | 5.5 | 6.4 | 13.9 | 11.8 |
| BSI NANO | 13.2 | 4.0 | 18.1 | 10.2 |
| BEST | 2.4 | 6.3 | 7.2 | 13.9 |
| Corporate | 6.9 | 4.0 | 11.6 | 6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total capital expenditures | $30.3 | $24.5 | $56.3 | $46.0 |
| Depreciation and Amortization: |  |  |  |  |
| BSI BioSpin | $11.2 | $10.4 | $21.6 | $18.6 |
| BSI CALID | 23.4 | 15.4 | 43.2 | 25.1 |
| BSI NANO | 17.1 | 15.9 | 33.8 | 29.3 |
| BEST | 2.4 | 2.1 | 4.5 | 4.1 |
| Corporate | 2.0 | 1.3 | 3.4 | 2.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total depreciation and amortization | $56.1 | $45.1 | $106.5 | $79.9 |

---

Total assets by segment are as follows (in millions):

---

| | | |
|:---|:---|:---|
|  | **June 30,<br>2025** | **December 31,<br>2024** |
| Assets: |  |  |
| BSI BioSpin, BSI CALID, BSI NANO & Corporate | $6192.6 | $5648.4 |
| BEST | 191.2 | 199.8 |
| Eliminations and other (a) | (44.0) | (41.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $6339.8 | $5806.7 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.*

The Company is unable, without unreasonable effort or expense, to disclose the amount of total assets by the BSI BioSpin, BSI CALID, BSI NANO Segments, and the Corporate function. Furthermore, the Company's chief operating decision maker does not receive long-lived asset information individually by these reportable segments and Corporate.

**8.** **Weighted Average Shares Outstanding**

The following table sets forth the computation of basic and diluted weighted average common shares outstanding (amounts in millions of shares):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average common shares outstanding - basic | 151.6 | 147.4 | 151.6 | 146.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock options and restricted stock units | 0.1 | 0.6 | 0.2 | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average common shares outstanding - diluted | 151.7 | 148.0 | 151.8 | 147.0 |

---

The following common share equivalents have been excluded from the computation of diluted weighted average common shares outstanding, as their effect would have been anti-dilutive (amounts in millions of shares):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Stock options | 0.5 | 0.2 | 0.4 | 0.2 |
| Unvested restricted stock units | 0.6 |  | 0.6 |  |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**9.** **Other Charges, Net** 

The components of other charges, net are as follows (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Acquisition-related expenses, net (a) | $2.8 | $17.5 | $9.0 | $21.6 |
| Acquisition-related litigation charges | 4.0 | 1.4 | 22.6 | 1.5 |
| Restructuring charges | 2.9 | 1.2 | 10.5 | 4.7 |
| Information technology transformation costs (b) | 2.8 | 1.9 | 5.8 | 2.7 |
| Other | 1.9 | 1.0 | 3.4 | 3.4 |
| Other charges, net | $14.4 | $23.0 | $51.3 | $33.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;*a) Acquisition-related expenses relate primarily to transaction costs on potential and consummated acquisitions, integration costs of newly acquired entities, and stock-based compensation expense related to the fair value changes of hybrid instruments.*

&nbsp;&nbsp;&nbsp;&nbsp;*b) The Information technology ("IT") transformation costs are related to an IT transformation initiative that is a multi-year project aimed at updating and integrating our global enterprise resource planning and human resource information systems.*

**10.** **Restructuring** 

The following table presents restructuring costs by segment as included within the Company's consolidated statements of operations for the periods reported (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Cost of revenues: |  |  |  |  |
| BSI BioSpin | $0.2 | $0.2 | $1.2 | $0.3 |
| BSI CALID | 0.6 | 0.8 | 1.8 | 0.8 |
| BSI NANO | 3.6 | 3.9 | 4.0 | 7.5 |
| &nbsp;&nbsp;Total Cost of revenues | $4.4 | $4.9 | $7.0 | $8.6 |
| Other charges, net: |  |  |  |  |
| BSI BioSpin | $(2.5) | $0.2 | $3.3 | $0.2 |
| BSI CALID | 2.2 | (0.1) | 3.2 | (0.1) |
| BSI NANO | 2.0 | 1.1 | 2.8 | 4.0 |
| Corporate | 1.2 |  | 1.2 | 0.6 |
| &nbsp;&nbsp;Total Other charges, net | $2.9 | $1.2 | $10.5 | $4.7 |
| &nbsp;&nbsp;Total | $7.3 | $6.1 | $17.5 | $13.3 |

---

The following table sets forth the changes in restructuring reserves, excluding costs of $3.8 million for scrapping expired or expiring inventory, for the periods reported (in millions):

---

| | | | |
|:---|:---|:---|:---|
|  | **Total** | **Severance** | **Exit Costs** |
| Balance at December 31, 2024 | $7.2 | $4.6 | $2.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 13.7 | 11.6 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash payments | (12.1) | (7.8) | (4.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, non-cash adjustments and foreign currency effect | 0.9 | 0.8 | 0.1 |
| Balance at June 30, 2025 | $9.7 | $9.2 | $0.5 |

---

*Bruker Cellular Analysis restructuring plan:* During the three months ended June 30, 2025 and 2024, in connection with the Bruker Cellular Analysis restructuring plan, the Company recorded and accrued severance and termination charges of $0.7 million and $2.6 million, respectively, and made payments of $0.7 million and $3.7 million, respectively. During the six months ended June 30, 2025 and 2024, in connection with the Bruker Cellular Analysis restructuring plan, the Company recorded and accrued severance and termination charges of $1.2 million and $6.5 million, respectively, and made payments of $3.7 million and $10.7 million, respectively. As it relates to the consolidation of leased BCA facilities, the Company recorded an impairment charge against operating lease right of

------

[**<u>**Table of Contents**</u>**](#toc_page)

use assets of $0.3 million and $1.5 million in the three and six months ended June 30, 2024, respectively. The Company did not have similar charges during the three and six months ended June 30, 2025. During the three and six months ended June 30, 2025, in connection with the Bruker Cellular Analysis restructuring plan, the Company charged $2.5 million to product restructuring costs due to scrapping of expired or expiring inventories. During the three and six months ended June 30, 2024, in connection with the Bruker Cellular Analysis restructuring plan, the Company charged $1.9 million and $4.7 million, respectively, to product restructuring costs due to scrapping of expired or expiring inventories. Refer to *Note 12, Restructurings and Asset Impairments* of the Annual Report on Form 10-K for the year ended December 31, 2024 for further information on this restructuring plan.

*Corporate wide and other restructuring plans:* The Company has previously incurred charges related to restructuring actions impacting the reportable segments at various locations across North America, Europe, and Asia. This includes workforce right-sizing actions resulting in severance and transition costs, costs related to the consolidation of facilities resulting in asset impairment, and accelerated depreciation charges. In the second quarter of 2025, the Company initiated a corporate-wide restructuring program to be implemented across multiple functions and geographies to address challenges in the current business environment. We anticipate additional restructuring charges in the third and fourth quarter of 2025 with activities under these plans expected to be completed by 2026.

**11.** **Interest and Other Income (Expense), Net**

The components of interest and other income (expenses), net are as follows (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Interest income | $2.7 | $2.4 | $5.8 | $5.0 |
| Interest expense | (15.7) | (15.7) | (28.8) | (20.7) |
| Impairment of minority investments |  | (20.2) | (1.9) | (20.2) |
| Exchange gains (losses), net on foreign currency transactions | 1.4 | 9.0 | 5.7 | 17.9 |
| Other income | 0.2 | 0.3 | 1.1 | 0.6 |
| &nbsp;&nbsp;Interest and other income (expense), net | $(11.4) | $(24.2) | $(18.1) | $(17.4) |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**12.** **Provision for Income Taxes** 

The components of provision for income taxes are as follows (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Income tax provision (benefit) | $(3.1) | $16.1 | $5.6 | $35.9 |
| Effective tax rates (a) | Not meaningful | 67.4% | 21.9% | 37.6% |
| Penalties and interest (recorded in provision for <br> income taxes for unrecognized tax benefits) | $0.8 | $(3.4) | $1.2 | $(2.2) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) For the three months ended June 30, 2025, the rate is not meaningful and was due to one-time favorable discrete events recorded during the period. The decrease in the Company's effective tax rate for the six months June 30, 2025 was primarily due to changes in jurisdictional mix and net favorable discrete activities.*

The table below summaries unrecognized tax benefits and accrued interest and penalties components (in millions):

---

| | | |
|:---|:---|:---|
|  | **June 30,<br>2025** | **December 31,<br>2024** |
| Unrecognized tax benefits (a) | $72.1 | $63.7 |
| Accrued interest and penalties (b) | $6.6 | $5.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) This excludes penalties and interest. If these unrecognized tax benefits were recognized, there would be a reduction of the Company's effective tax rate.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*b) These are related to uncertain tax positions and were included in other long-term liabilities on the Company's unaudited condensed consolidated balance sheets.*

The Company files tax returns in the United States, which include federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States, and Switzerland to be its significant tax jurisdictions. The majority of the Company's earnings are derived in Germany and Switzerland. Accounting for the various federal and local taxing authorities, the statutory rates for 2025 are approximately 30.0% and 20.0% for Germany and Switzerland, respectively. The mix of earnings in those two jurisdictions resulted in an increase of approximately 7.5% from the U.S. statutory rate of 21.0% in the six months ended June 30, 2025.

The Organization for Economic Co-operation and Development ("OECD") introduced its Pillar Two Framework Model Rules ("Pillar 2"), which provides guidance for a global minimum tax. Various countries have either enacted or are in the process of enacting legislation to implement this framework. The Company's income tax provision for the three and six months ended June 30, 2025, reflects currently enacted legislation and guidance related to the model rules. This enacted legislation and guidance had an impact on the Company's income tax provision, resulting in an increase to its effective tax rate of 2.3% for the six months ended June 30, 2025. The Company continues to monitor the countries in which it operates as they enact legislation implementing Pillar 2.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027.

On July 18, 2025, the German Federal Council enacted legislation to gradually reduce the corporate income tax rate from 15% to 10% over the period 2028 to 2032.

The Company will assess the impact of these changes on its consolidated financial statements and will record them during the third quarter of 2025, which is the period of enactment.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**13.** **Inventories** 

Inventories consisted of the following (in millions):

---

| | | |
|:---|:---|:---|
|  | **June 30,<br>2025** | **December 31,<br>2024** |
| Raw materials | $427.4 | $388.7 |
| Work-in-process | 394.0 | 348.9 |
| Finished goods | 273.2 | 228.5 |
| Demonstration units | 123.7 | 101.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Inventories | $1218.3 | $1067.8 |

---

Finished goods include in-transit systems shipped to the Company's customers for which control has not passed to the customers. As of June 30, 2025 and December 31, 2024, the value of finished goods inventory-in-transit was $77.9 million and $53.6 million, respectively.

**14.** **Other Current Assets**

Other current assets consisted of the following (in millions):

---

| | | |
|:---|:---|:---|
|  | **June 30,<br>2025** | **December 31,<br>2024** |
| Unbilled receivables | $112.4 | $93.6 |
| Income and other taxes receivable *(note 12)* | 99.4 | 34.5 |
| Prepaid expenses | 49.7 | 35.1 |
| Deposits with vendors | 32.8 | 26.1 |
| Interest rate cross-currency swap agreements *(note 17)* | 7.3 | 10.7 |
| Lease receivable | 4.3 | 7.6 |
| Other assets | 23.9 | 28.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | $329.8 | $236.5 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**15.** **Debt** 

The Company's debt obligations consist of the following (in millions):

---

| | | |
|:---|:---|:---|
|  | **June 30,<br>2025** | **December 31,<br>2024** |
| <u>2024 term loan agreements:</u> |  |  |
| &nbsp;&nbsp;CHF loan due 2027 | $181.9 | $162.1 |
| &nbsp;&nbsp;CHF loan due 2029 | 183.1 | 162.1 |
| &nbsp;&nbsp;CHF loan due 2031 | 189.0 | 165.2 |
| <u>2019 term loan agreement:</u> |  |  |
| &nbsp;&nbsp;USD loan quarterly payments of $3.8 million and balloon payment due December 2026 | 255.8 | 263.3 |
| <u>Note Purchase Agreements (NPA – Senior notes):</u> |  |  |
| &nbsp;&nbsp; 2024 notes due April 15, 2034 - CHF 50 million 2.56% (a) | 63.0 | 55.1 |
| &nbsp;&nbsp; 2024 notes due April 15, 2036 - CHF 146 million 2.62% and CHF 50 million 2.60% (a) | 246.9 | 215.9 |
| &nbsp;&nbsp; 2024 notes due April 15, 2039 - CHF 135 million 2.71% and CHF 50 million 2.62% (a) | 233.1 | 203.8 |
| &nbsp;&nbsp; 2021 notes due December 8, 2031 - CHF 300 million 0.88% (a) | 378.0 | 330.5 |
| &nbsp;&nbsp; 2019 notes due December 11, 2029 - CHF 297 million 1.01% (a) | 374.2 | 327.2 |
| &nbsp;&nbsp; 2021 notes due December 8, 2031 - EUR 150 million 1.03% (a) | 176.5 | 155.3 |
| CHF revolving loan (in U.S. Dollars) under the 2024 Revolving Credit Agreement (b) | 122.1 | 27.5 |
| Other loans | 15.2 | 11.9 |
| Unamortized debt issuance costs | (2.8) | (3.1) |
| &nbsp;&nbsp;Total notes and loans outstanding | $2416.0 | $2076.8 |
| Finance lease obligations | 19.3 | 17.5 |
| &nbsp;&nbsp;Total debt | $2435.3 | $2094.3 |
| Current portion of long-term debt and finance lease obligations | (55.7) | (32.5) |
| &nbsp;&nbsp;Total long-term debt, less current portion | $2379.6 | $2061.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) The fair value of the Company's long-term fixed interest rate debt was $1,426.7 million and $1,278.9 million as of June 30, 2025, and December 31, 2024, respectively.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*b) Subsequent to June 30, 2025, and up until the date of filing this Quarterly Report on Form 10-Q, the Company borrowed approximately $457.4 million of debt under the 2024 Amended and Restated Revolving Credit Agreement. Any debt outstanding under the 2024 Amended and Restated Revolving Credit Agreement is due at the end of its term in January 2029, and borrowings under this agreement may also be prepaid, at the Company's option, in whole or in part without premium or penalty.* 

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Significant borrowings and repayments:*** 

The following table summarizes the Company's debt borrowings and repayments from long-term debt for the six months ended June 30, 2025 and 2024 (amounts in millions):

---

| | | |
|:---|:---|:---|
|  | **June 30, <br>2025** | **June 30, <br>2024** |
| <u>Proceeds from long-term debt:</u> |  |  |
| &nbsp;&nbsp;CHF notes under various 2024 Note Purchase Agreements | $— | $472.1 |
| &nbsp;&nbsp;CHF notes under the 2024 Term Loan Agreement |  | 329.5 |
| &nbsp;&nbsp;Other | 2.9 | 4.1 |
| Proceeds from long-term debt - Total | $2.9 | $805.7 |
| <u>Repayment of long-term debt:</u> |  |  |
| &nbsp;&nbsp;USD notes under the 2012 Note Purchase Agreement | $— | $(100.0) |
| &nbsp;&nbsp;USD notes under the 2019 Term Loan Agreement | (7.5) | (7.5) |
| &nbsp;&nbsp;CHF notes under the 2024 Term Loan Agreement | (5.6) |  |
| &nbsp;&nbsp;Other | (9.2) | (10.5) |
| Repayment of long-term debt - Total | $(22.3) | $(118.0) |

---

***Revolving Credit Facility****:* 

As of June 30, 2025, the maximum commitments and net amounts available under (i) the 2024 Revolving Credit Agreement and (ii) other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand are as follows (dollars in millions):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Weighted<br>Average<br>Interest Rate** | **Total Amount<br>Committed by<br>Lenders** | **Outstanding<br>Borrowings** | **Outstanding<br>Letters of<br>Credit** | **Total<br>Amount<br>Available** |
| 2024 Amended and Restated Credit <br>&nbsp;&nbsp;&nbsp;&nbsp; Agreement | 0.43% | $900.0 | $122.1 | $0.7 | $777.2 |
| Bank guarantees and working capital line | varies | 184.0 |  | 184.0 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revolving lines of credit |  | $1084.0 | $122.1 | $184.7 | $777.2 |

---

As of June 30, 2025, the Company was in compliance with the covenants of all debt agreements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**16.** **Fair Value of Financial Instruments** 

The Company measures the following financial assets and liabilities at fair value on a recurring basis. The following tables set forth the Company's financial instruments and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **June 30, 2025** | **Total** | **Quoted Prices<br>in Active<br>Markets<br>Available<br>(Level 1)** | **Significant<br>Other<br>Observable<br>Inputs<br>(Level 2)** | **Significant<br>Unobservable<br>Inputs<br>(Level 3)** |
| Assets: |  |  |  |  |
| Time deposits and money market funds | $0.6 | $0.6 | $— | $— |
| Interest rate and cross-currency swap agreements (*note 17*) | 9.2 |  | 9.2 |  |
| Forward currency contracts | 0.2 |  | 0.2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets recorded at fair value | $10.0 | $0.6 | $9.4 | $— |
| Liabilities: |  |  |  |  |
| Contingent consideration (*note 18*) | $13.9 | $— | $— | $13.9 |
| Hybrid instruments liabilities (*note 19*) | 83.6 |  |  | 83.6 |
| Interest rate and cross-currency swap agreements (*note 17*) | 42.8 |  | 42.8 |  |
| Forward currency contracts | 3.3 |  | 3.3 |  |
| Equity interest purchase option liability (a) | 17.0 |  |  | 17.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities recorded at fair value | $160.6 | $— | $46.1 | $114.5 |
| **December 31, 2024** | **Total** | **Quoted Prices<br>in Active<br>Markets<br>Available<br>(Level 1)** | **Significant<br>Other<br>Observable<br>Inputs<br>(Level 2)** | **Significant<br>Unobservable<br>Inputs<br>(Level 3)** |
| Assets: |  |  |  |  |
| Time deposits and money market funds | $17.2 | $— | $17.2 | $— |
| Interest rate and cross-currency swap agreements *(note 17)* | 21.8 |  | 21.8 |  |
| Forward currency contracts | 6.0 |  | 6.0 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets recorded at fair value | $45.0 | $— | $45.0 | $— |
| Liabilities: |  |  |  |  |
| Contingent consideration (note 18) | $17.3 | $— | $— | $17.3 |
| Hybrid instruments liabilities (note 19) | 78.1 |  |  | 78.1 |
| Interest rate and cross-currency swap agreements (note 17) | 17.2 |  | 17.2 |  |
| Forward currency contracts | 0.5 |  | 0.5 |  |
| Equity interest purchase option liability (a) | 14.9 |  |  | 14.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities recorded at fair value | $128.0 | $— | $17.7 | $110.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Equity interest purchase option liability is related to NovAliX, refer to Note 4, Minority and equity-method investments, for more information.*

Refer to *Note 2, Summary of Significant Accounting Policies* to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, for further information on the risks and valuation methodology used for assets and liabilities measured or disclosed at fair value.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**17.** **Derivative Instruments and Hedging Instruments** 

The Company's major exposures relate to foreign exchange rate, interest rate, and commodity price risks. Risk management activities related to these risks are as follows:

***Foreign Exchange Rate Risk:*** 

The Company's exposure to foreign exchange rate risk includes exchange risk as a result of non-U.S. operations having functional currencies other than the U.S. Dollar, which is managed by cross-currency interest rate swap agreements and long-term debt designated as net investment hedges. As of June 30, 2025, the Company had several cross-currency interest rate swap agreements that qualify for hedge accounting with a notional value of $127.9 million of U.S. Dollar to Swiss Franc and a notional value of $127.9 million of U.S. Dollar to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of its Euro and Swiss Franc denominated net asset investments.

In addition, the Company has foreign currency exposure at a transaction level, and this is addressed by forward currency contracts for significant exposures which have not been designated as accounting hedges.

***Interest Rate Risk:*** 

The Company's exposure to interest rate risk relates primarily to outstanding variable rate debt under the U.S. Dollar denominated 2019 Term Loan and adverse movements in the related market rates. This exposure is managed as part of a cross-currency interest rate swap which involves the Company paying-fixed receiving-floating. The objective of this designated cash flow hedge is to offset the variability of cash flows on term loan debt interest payments attributable to changes in SOFR, a contractually specified rate. The difference between the interest rate received and paid under the interest rate and cross-currency swap agreements is recorded in Interest and other income (expense), net in the consolidated statements of operations and comprehensive income.

***Commodity Price Risk:*** 

The Company has arrangements with certain customers under which it has a firm commitment to deliver copper-based superconductors at a fixed price. In order to minimize the volatility that fluctuations in the price of copper have on the Company's sales of these commodities, the Company enters into commodity hedge contracts. As commodity contracts settle, gains (losses) related to changes in fair values are included within revenues.

The following table presents the Company's notional amounts outstanding under foreign exchange contracts, cross-currency interest rate swap agreements, and long-term debt designated as net investment hedges, as well as the respective fair value of the instruments (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **June 30,<br>2025** | **June 30,<br>2025** | **December 31,<br>2024** | **December 31,<br>2024** |
|  | **Notional <br>(in USD)** | **Fair Value** | **Notional <br>(in USD)** | **Fair Value** |
| **Derivatives designated as hedging instruments** |  |  |  |  |
| Interest rate cross-currency swap agreements |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets |  | $7.3 |  | $10.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets |  | 1.9 |  | 11.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities |  | (42.8) |  | (17.2) |
|  | $255.8 | $(33.6) | $263.3 | $4.6 |
| Long-term debt |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | 1660.7 | (216.2) | 1453.0 | (8.5) |
| **Total derivatives designated as hedging instruments** | $1916.5 | $(249.8) | $1716.3 | $(3.9) |
| **Derivatives not designated as hedging instruments** |  |  |  |  |
| Forward currency contracts |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | $52.9 | $0.2 | $841.9 | $6.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 956.6 | (3.3) | 78.6 | (0.5) |
| **Total derivatives not designated as hedging instruments** | $1009.5 | $(3.1) | $920.5 | $5.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total derivatives** | $2926.0 | $(252.9) | $2636.8 | $1.6 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

The following table is a summary of the gain (loss) included in Interest and other income (expense), net in the consolidated statements of operations and comprehensive income related to the derivative instruments described above (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Derivatives not designated as hedging instruments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Forward currency contracts | $(26.2) | $(7.1) | $(22.0) | $(5.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Embedded derivatives in purchase and delivery contracts | 0.9 | 0.2 | 1.1 | (1.1) |
|  | (25.3) | (6.9) | (20.9) | (6.2) |
| **Derivatives designated as cash flow hedging instruments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate cross-currency swap agreements | $1.8 | $2.6 | $3.7 | $5.3 |
| **Derivatives designated as net investment hedging instruments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate cross-currency swap agreements | 1.2 | 1.4 | 2.5 | 2.9 |
|  | 3.0 | 4.0 | 6.2 | 8.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $(22.3) | $(2.9) | $(14.7) | $2.0 |

---

The following table is a summary of the gain (loss) included in Accumulated other comprehensive income, net of tax in the consolidated statements of operations and comprehensive income related to the derivative instruments described above (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Derivatives designated as cash flow hedging instruments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate cross-currency swap agreements | $(1.4) | $(0.9) | $(3.5) | $0.5 |
|  | (1.4) | (0.9) | (3.5) | 0.5 |
| **Derivatives designated as net investment hedging instruments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate cross-currency swap agreements | $(20.6) | $(0.3) | $(26.0) | $9.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | (126.9) | (6.3) | (158.0) | 44.2 |
|  | (147.5) | (6.6) | (184.0) | 54.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $(148.9) | $(7.5) | $(187.5) | $54.6 |

---

**18.** **Contingent Consideration** 

The following table sets forth the changes in contingent consideration liabilities (in millions):

---

| | |
|:---|:---|
| Balance at December 31, 2024 | $17.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period additions |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period adjustments | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period settlements | (5.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency effect | 0.7 |
| Balance at June 30, 2025 | $13.9 |

---

Changes in fair value subsequent to acquisition are recognized in Acquisition-related expenses, net included in Other Charges, net, in the consolidated statements of operations. Contingent consideration payments in excess of the acquisition date fair value are included in net cash provided by operating activities and the original acquisition date values are included in net cash provided by (used in) financing activities in the consolidated statements of cash flows.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**19.** **Hybrid instruments liabilities** 

Related to certain other majority owned acquisitions, the Company has entered into agreements with the noncontrolling interest holders that provide the Company with the right to purchase, and the noncontrolling interest holders with the right to sell the remaining ownerships for cash at contractually defined redemption values.

The following table sets forth the changes in hybrid instruments liability (in millions):

---

| | |
|:---|:---|
| Balance at December 31, 2024 | $78.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period adjustments | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period settlements |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency effect | 3.8 |
| Balance at June 30, 2025 | $83.6 |

---

The Level 3 fair value measurements of our hybrid instrument liabilities include the following significant unobservable inputs:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Hybrid Instrument Liabilities | Valuation Technique | Unobservable Input | Range | Weighted Average (a) |
| Put / Call Options | Option Pricing Model | Revenue Risk Premium | 1.6% - 12.6% | 10.6% |
|  |  | EBITDA Risk Premium | 10.1% - 25.1% | 21.4% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Unobservable inputs were weighted by the relative fair value of the hybrid instrument liabilities.* 

**20.** **Commitments and Contingencies** 

The Company's product offerings include technologies and related intellectual property rights that are either developed or acquired. Such technologies and rights, particularly patents, are a significant part of ongoing product development and differentiation. Lawsuits, claims, and proceedings of a nature that claim infringement of patents or patent licenses owned by others are considered normal to the business and may be pending from time to time against the Company. Intellectual property litigation is inherently complex and unpredictable. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify.

Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding related to patents, products, and other matters, is considered probable and the amount can be reasonably estimated, or a range of loss can be determined. If the estimate of a probable loss is a range and no amount within the range is more likely, management's best estimate is represented by the minimum amount of the range. If a material loss is not reasonably estimable, but is considered probable, or a material loss is reasonably possible, but not probable, disclosure would be provided below. The outcome of any of these proceedings cannot be accurately predicted, and the ultimate resolution of any of these existing matters, net of amounts accrued in the Company's balance sheet, may have a material adverse effect on the Company's business or financial condition.

Third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; (iii) payment of significant damages, royalties, penalties, and/or license fees to third parties; and, (iv) with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.

At June 30, 2025, and December 31, 2024, the accrual for several legal matters that were deemed to be both probable and estimable was $27.3 million and $86.0 million, respectively. In management's opinion, the Company is not currently involved in any legal proceedings other than those specifically identified below, individually or in the aggregate, that could materially adversely impact our operating results and cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated. While the Company believes it has meritorious defenses for the matters described below, the ultimate resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.

------

[**<u>**Table of Contents**</u>**](#toc_page)

In connection with the Company's acquisition of PhenomeX Inc. ("PhenomeX") on October 2, 2023, the Company's wholly owned subsidiary, Bruker Cellular Analysis, Inc., was substituted as a party into the existing patent litigation between PhenomeX and AbCellera Biologics Inc. ("AbCellera") related to PhenomeX's Beacon instruments and Opto products. The University of British Columbia ("UBC"), the owner and licensor to AbCellera of the asserted patents, is a co-plaintiff in the litigation. The plaintiffs' complaint seeks unspecified damages and injunctive relief.

In connection with the acquisition of NanoString on May 6, 2024, the Company assumed certain of its liabilities, including the liabilities associated with NanoString's litigation matters with 10x Genomics, Inc. ("10x") related to NanoString's GeoMx Digital Spatial Profiler products, NanoString's CosMx Spatial Molecular Imager products, and 10x's Visium Spatial Gene Expression system and related products. On May 12, 2025, the Company and 10x entered into a settlement agreement resolving these litigation matters, with global patent cross license agreements between the two companies. The settlement includes an agreement by the Company to pay $68.0 million to 10x in four equal quarterly installments, beginning in third quarter of 2025 and, effective as of the settlement date, the Company will pay royalties on sales of GeoMx and CosMx products until the expiration of the applicable licensed patents. In connection with the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in several countries, including actions pending in the United States, in Germany, and before the European Unified Patent Court, have been, or are being, withdrawn. In accounting for the settlement agreement, the Company allocated the $68.0 million payment between amounts representing the settlement of the past liability related to patent infringement claims and the future cost of doing business associated with the license agreements. As a result, the Company recognized an intangible asset and recorded the remaining settlement amount under other current liabilities in the consolidated balance sheets in the second quarter of 2025.

**21.** **Shareholders' Equity** 

At June 30, 2025, the Company did not have any preferred stock issued or outstanding (5,000,000 shares authorized with $0.01 par value).

At June 30, 2025, the Company had 182,695,537 shares issued and 151,715,927 shares outstanding of common stock (260,000,000 shares authorized with $0.01 par value).

***Public Offering***

In May 2024, the Company completed an underwritten public offering (the "Offering") in which the Company issued and sold 6,000,000 shares of its common stock at a public offering price of $67.29 per share. The Company received net proceeds of approximately $403.0 million after deducting underwriting fees and other offering expenses. The Offering was made pursuant to an automatically effective registration statement on Form S-3 and accompanying prospectus filed with the SEC on May 29, 2024, and a final prospectus relating to the Offering filed with the SEC on May 31, 2024. The Company did not complete any underwritten public offering during the three and six months ended June 30, 2025.

***Share Repurchase Program*** 

In May 2023, the Company's Board of Directors approved a share repurchase program (the "2023 Repurchase Program") authorizing the purchase of up to $500.0 million of the Company's common stock over a two-year period, in amounts, at prices, and at such times as management deems appropriate, subject to market conditions, legal requirements, and other considerations.

The following table presents the share purchase activity under the 2023 Repurchase Program for the periods reported (in millions except share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Shares purchased |  |  | 200731 |  |
| Aggregate cost of shares repurchased | $— | $— | $10.0 | $— |
| Dollar value of shares that may yet be purchased under the program (a) | $359.9 | $369.9 | $359.9 | $369.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Authorization for the remaining $359.9 million on the 2023 Repurchase Program expired in May 2025.*

At June 30, 2025 the Company held 30,979,610 shares of treasury stock at cost.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Stock-Based Compensation*** 

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of operations and comprehensive income (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Stock options | $0.5 | $0.4 | $1.0 | $0.9 |
| Restricted stock units | 4.8 | 4.4 | 9.5 | 8.6 |
| Employee Stock Purchase Plan | 0.4 | 0.3 | 0.8 | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense | $5.7 | $5.1 | $11.3 | $10.0 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Cost of product revenue | $0.5 | $0.4 | $1.1 | $0.8 |
| Selling, general and administrative | 4.5 | 4.1 | 8.8 | 8.0 |
| Research and development | 0.7 | 0.6 | 1.4 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense | $5.7 | $5.1 | $11.3 | $10.0 |

---

In addition to the awards above, the Company recorded stock-based compensation expense within other charges, net of $0.7 million and $1.7 million in the three months ended June 30, 2025, and 2024, respectively, and $1.3 million and $2.2 million in the six months ended June 30, 2025 and 2024, respectively, related to the fair value changes of hybrid instruments associated with the option rights of certain minority shareholders of the Company's majority owned acquisitions.

At June 30, 2025, the Company expected to recognize pre-tax stock-based compensation expense of $3.5 million associated with outstanding stock option awards granted under the Company's stock plans over the weighted average remaining service period of 2.3 years. The Company also expects to recognize additional pre-tax stock-based compensation expense of $36.1 million associated with outstanding restricted stock units granted under the Company's 2016 Incentive Compensation Plan over the weighted average remaining service period of 2.3 years.

In May 2025, the Bruker Corporation 2026 Incentive Compensation Plan (the "2026 Plan") was approved by the Company's stockholders. The 2026 Plan will be effective as of February 19, 2026 (the "Effective Date"), which will be the date immediately following the date on which the Bruker Corporation 2016 Incentive Compensation Plan (the "Prior Plan") expires. No additional awards will be granted under the Prior Plan on or after the Effective Date. The 2026 Plan provides for the issuance of up to 12,000,000 shares of the Company's common stock. The 2026 Plan will be administered by the Compensation Committee of the Board or another committee appointed by the Board (the "Committee") and provides for grants of awards to non-employee directors, employees, and certain key advisors of the Company, and its subsidiaries in the form of nonqualified and incentive options, stock awards, stock units, stock appreciation rights, cash-based awards, and other awards. The Committee has the authority to determine which employees will receive awards, the amount of any awards, and other terms and conditions of such awards. The 2026 Plan will terminate on May 28, 2035, unless terminated earlier pursuant to its terms.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** 

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2024. The dollar amounts listed in the tables presented in Management's Discussion and Analysis of Financial Condition and Results of Operations are in millions of U.S. Dollars.

Any statements other than statements of historical fact contained in Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Without limiting the foregoing, the words "believe," "anticipate," "plan," "expect," "seek," "may," "will," "intend," "estimate," "should" and similar expressions are intended to identify forward-looking statements.

Forward-looking statements include, but are not limited to, statements regarding:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of supply chain challenges on our business and operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our working capital requirements and the sufficiency of our cash, borrowings, and proceeds of indebtedness to fund our operations and investment activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our plans to make capital investments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of changes to tax and accounting rules, and changes in law, including the One Big Beautiful Bill Act (the "Act");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•fluctuations in estimates impacting costs related to our self-funded health insurance plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding backlog and revenue;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations and the impact of our restructuring initiatives or success of our acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of our global IT transformation activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of foreign currency exchange rates and changes in commodity prices; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•any other statements that address events or developments that the Company intends or believes will or may occur in the future.

Actual results may differ from those referred to in any forward-looking statements due to a number of factors, including, but not limited to, the risks described in Part I, Item 1A "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and in this Quarterly Report on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

We can experience quarter-to-quarter fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•general economic conditions, including inflation, the threat of recession, financial liquidity, currency volatility or devaluation, supply chain or manufacturing capabilities, uncertain economic conditions in the United States and abroad, and additional tariffs, including those imposed or that may be imposed by the presidential administration in the U.S;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•geopolitical tensions, including those on our customers, such as the conflict between Russia and Ukraine and related economic sanctions, the conflict in the Middle East and surrounding areas, the possible expansion of such conflicts and potential geopolitical consequences, the ongoing tensions between the United States and China, tariff and trade policy changes, and increasing potential of conflict involving countries in Asia that are significant to the Company's supply chain operations, such as Taiwan and China;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of potential governmental investigations involving regulatory, marketing, and other business practices, which may result in the commencement of civil and criminal proceedings, fines, penalties, and administrative remedies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•potential energy shortages in Europe where the Company has significant operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impacts of climate change and certain weather-related disruptions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the timing of governmental stimulus programs and academic research budgets;

------

[**<u>**Table of Contents**</u>**](#toc_page)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers, and full payment is received;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•foreign currency exchange rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the worldwide shortage of semiconductor chips, components, and raw materials, such as copper;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in raw material, component, and logistics costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the time it takes for us to receive critical materials to manufacture our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the time it takes to satisfy local customs requirements and other export/import requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the time it takes for customers to construct or prepare their facilities for our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the time required to obtain governmental licenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to identify suitable acquisition targets and successfully integrate and manage acquired business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•costs related to acquisitions of technology or businesses.

Several of these factors have in the past affected and may continue to affect the amount and timing of revenue recognized on sales of our products and receipt of related payments, and will likely continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter's operating performance.

**OVERVIEW** 

We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular, and cellular levels. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major research and development and manufacturing centers in Europe, Asia and North America, and we have commercial offices located throughout the world. Bruker is organized into four reportable segments: the Bruker Scientific Instruments (BSI) BioSpin Segment, the BSI CALID Segment, the BSI NANO Segment, and the Bruker Energy & Supercon Technologies (BEST) Segment.

**Consolidated Results**

The following table presents a summary of our consolidated results as of the three and six months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| ***GAAP Financial Measures:*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenue | $797.4 | $800.7 | $1598.8 | $1522.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenue year-on-year Growth Rate | (0.4)% | 17.4% | 5.0% | 11.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | $357.9 | $384.6 | $749.1 | $737.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit Margin | 44.9% | 48.0% | 46.9% | 48.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating Income | $11.9 | $48.1 | $43.7 | $112.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating Income Margin | 1.5% | 6.0% | 2.7% | 7.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used by) operating activities | $(127.5) | $1.1 | $(62.5) | $22.9 |
| ***Non-GAAP Financial Measures (see 'Non-GAAP Measures' below):*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Constant-exchange rate (CER) currency revenue | $774.0 | $808.1 | $1585.8 | $1530.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Constant-exchange rate (CER) currency revenue year-on-year growth rate | (3.3)% | 18.5% | 4.2% | 12.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Organic Revenue | $744.4 | $732.6 | $1487.0 | $1429.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Organic Revenue year-on-year growth rate | (7.0)% | 7.4% | (2.3)% | 4.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Gross Profit | $387.2 | $411.1 | $798.1 | $780.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Gross Profit Margin | 48.6% | 51.3% | 49.9% | 51.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Operating Income | $72.0 | $110.7 | $173.7 | $211.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Operating Income Margin | 9.0% | 13.8% | 10.9% | 13.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Free Cash Flow | $(148.8) | $(23.5) | $(109.8) | $(23.1) |

---

Discussion of GAAP financial measures follows in the Results of Operations paragraphs.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Non-GAAP Financial Measures** 

***Uses and definitions:***

Although our unaudited condensed consolidated financial statements have been prepared in accordance with GAAP, we believe that describing revenue excluding the effects of foreign currency, and expenses excluding costs related to restructuring actions, acquisitions, and related integration expenses, amortization of acquired intangible assets, costs associated with our global information technology, transition initiatives, and other costs ("non-GAAP adjustments"), provides meaningful supplemental information regarding our performance but should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. We rely internally on certain measures that are not calculated according to GAAP. These measures include constant exchange rate ("CER") currency revenue growth, organic revenue growth, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, and free cash flow.

Our management believes that these financial measures provide relevant and useful information that is widely used by equity analysts, investors, and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance and are useful measures to evaluate our continuing business. Additionally, management believes free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, investments in our business, acquisitions, share repurchases, dividends, and repayment of debt.

We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on such non-GAAP measures and use this information for our planning and forecasting activities. These measures may also be useful to investors in evaluating the underlying operating performance of our business. The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP, and it may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies.

We define our non-GAAP financial measures as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•CER currency revenue growth as GAAP revenue excluding the effect of changes in foreign currency translation rates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Organic revenue growth as GAAP revenue excluding the effect of changes in foreign currency translation rates and acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Non-GAAP gross profit as GAAP gross profit excluding certain non-GAAP adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Non-GAAP gross profit margin as GAAP gross profit margin excluding the impact of certain non-GAAP adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Non-GAAP operating income as GAAP operating income excluding non-GAAP adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Non-GAAP operating income margin as GAAP operating income margin excluding the impact of non-GAAP adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Free cash flow as GAAP net cash provided by operating activities less additions to property, plant, and equipment.

***Reconciliations of GAAP to Non-GAAP financial measures:***

*GAAP revenue to non-GAAP CER currency revenue:* 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| GAAP revenue | $797.4 | $800.7 | $1598.8 | $1522.4 |
| Effect of changes in foreign currency translation rates | 23.4 | (7.4) | 13.0 | (8.4) |
| &nbsp;&nbsp;Non-GAAP CER currency revenue | $774.0 | $808.1 | $1585.8 | $1530.8 |
| *GAAP Revenue growth rate* | (0.4)% | *17.4%* | *5.0%* | *11.4%* |
| *Non-GAAP CER currency revenue growth rate* | (3.3)% | 18.5% | 4.2% | 12.0% |

---

The non-GAAP CER revenue decline in the three months ended June 30, 2025, compared to the year ago quarter, was driven primarily by slower demand in pharma and industrial markets for our life science instruments partially offset by higher revenue from prior year acquisitions. The increase in non-GAAP CER in the six months ended June 30, 2025, compared to the year ago period, reflects increased revenue from prior year acquisitions offset by reduced revenue from the weakened biopharma research markets.

------

[**<u>**Table of Contents**</u>**](#toc_page)

*GAAP revenue to non-GAAP Organic revenue:* 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| GAAP revenue | $797.4 | $800.7 | $1598.8 | $1522.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Non-GAAP adjustments:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions and divestitures | 29.6 | 75.5 | 98.8 | 101.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in foreign currency translation rates | 23.4 | (7.4) | 13.0 | (8.4) |
| **Non-GAAP Organic revenue** | $744.4 | $732.6 | $1487.0 | $1429.0 |
| *GAAP Revenue growth rate* | (0.4)% | *17.4%* | *5.0%* | *11.4%* |
| *Non-GAAP Organic revenue growth rate* | (7.0)% | *7.4%* | (2.3)% | *4.5%* |

---

The non-GAAP organic revenue decline in the three months and six months ended June 30, 2025, compared to the year-ago periods, was primarily a result of similar drivers to those described above under *GAAP revenue to non-GAAP CER currency revenue.*

*GAAP Gross Profit to non-GAAP Gross Profit:* 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Gross profit | $357.9 | 44.9% | $384.6 | 48.0% | $749.1 | 46.9% | $737.4 | 48.4% |
| Non-GAAP adjustments: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs | 4.4 | 0.6% | 4.9 | 0.6% | 7.0 | 0.4% | 8.6 | 0.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related costs | 2.8 | 0.4% | 8.7 | 1.1% | 5.1 | 0.3% | 11.7 | 0.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchased intangible amortization | 15.0 | 1.9% | 12.0 | 1.5% | 29.0 | 1.8% | 19.8 | 1.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other costs | 7.1 | 0.8% | 0.9 | 0.1% | 7.9 | 0.5% | 3.0 | 0.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP gross profit | $387.2 | 48.6% | $411.1 | 51.3% | $798.1 | 49.9% | $780.5 | 51.3% |

---

The decrease in Non-GAAP gross profit margin in the three months and six months ended June 30, 2025, compared to the year-ago periods, was driven by decline of revenue primarily as result of slower demand in pharma and industrial markets, combined with an increase in cost of goods sold due to higher U.S. tariffs and foreign exchange headwinds from a declining U.S. dollar.

*GAAP Operating income to non-GAAP Operating income:*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Operating income | $11.9 | 1.5% | $48.1 | 6.0% | $43.7 | 2.7% | $112.9 | 7.4% |
| Non-GAAP adjustments: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs | 7.3 | 0.9% | 6.1 | 0.8% | 17.5 | 1.1% | 13.3 | 0.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related costs | 5.5 | 0.7% | 26.0 | 3.2% | 14.1 | 0.9% | 33.1 | 2.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchased intangible amortization | 31.5 | 4.0% | 25.1 | 3.1% | 58.8 | 3.7% | 41.3 | 2.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related litigation charges | 4.0 | 0.5% | 1.4 | 0.2% | 22.6 | 1.4% | 1.5 | 0.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other costs | 11.8 | 1.4% | 4.0 | 0.5% | 17.0 | 1.1% | 9.3 | 0.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP operating income | $72.0 | 9.0% | $110.7 | 13.8% | $173.7 | 10.9% | $211.4 | 13.9% |

---

The decrease in our non-GAAP operating margin in the three and six months ended June 30, 2025, compared to the year-ago periods, was driven primarily by lower non-GAAP gross profit, the impact of foreign currency translation, and the impact of prior period acquisitions.

------

[**<u>**Table of Contents**</u>**](#toc_page)

*GAAP Net operating cash flow to non-GAAP Free cash flow:*

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** |
| GAAP net cash provided by (used in) operating activities | $(62.5) | $22.9 |
| Less: purchases of property, plant and equipment | (47.3) | (46.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Free cash flow | $(109.8) | $(23.1) |

---

For the six months ended June 30, 2025, our free cash flow decreased by $86.7 million compared to the same period in 2024, primarily due to lower net income and an increase in tax payments in the first half of 2025.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**RESULTS OF OPERATIONS** 

*Three Months Ended June 30, 2025, compared to the Three Months Ended June 30, 2024* 

***Consolidated Results*** 

The following table presents our results for the periods reported:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** |  |  |
|  | **2025** | **2024** | **Dollar<br>Change** | **Percentage<br>Change** |
| Product revenue | $634.7 | $654.4 | $(19.7) | (3.0)% |
| Service and other revenue | 162.7 | 146.3 | 16.4 | 11.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 797.4 | 800.7 | (3.3) | (0.4)% |
| Cost of product revenue | 346.1 | 326.0 | 20.1 | 6.2% |
| Cost of service and other revenue | 93.4 | 90.1 | 3.3 | 3.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue | 439.5 | 416.1 | 23.4 | 5.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 357.9 | 384.6 | (26.7) | (6.9)% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 231.4 | 221.3 | 10.1 | 4.6% |
| Research and development | 100.2 | 92.2 | 8.0 | 8.7% |
| Other charges, net | 14.4 | 23.0 | (8.6) | (37.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 346.0 | 336.5 | 9.5 | 2.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 11.9 | 48.1 | (36.2) | (75.3)% |
| Interest and other income (expense), net | (11.4) | (24.2) | 12.8 | (52.9)% |
| Income before income taxes, equity in income of<br> unconsolidated investees, net of tax, and noncontrolling <br> interests in consolidated subsidiaries | 0.5 | 23.9 | (23.4) | (97.9)% |
| Income tax provision (benefit) | (3.1) | 16.1 | (19.2) | (119.3)% |
| Equity in income (loss) of unconsolidated investees, net of tax | 0.6 | (0.2) | 0.8 | (400.0)% |
| Consolidated net income | 4.2 | 7.6 | (3.4) | (44.7)% |
| Net income (loss) attributable to noncontrolling interests in <br> consolidated subsidiaries | (3.4) |  | (3.4) |  |
| Net income attributable to Bruker Corporation | $7.6 | $7.6 |  | 0.0% |

---

***Revenue*** 

The following table presents revenue, change in revenue, and revenue growth by reportable segment for the periods reported:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** |  |  |
|  | **2025** | **2024** | **Dollar<br>Change** | **Percentage<br>Change** |
| BSI BioSpin | $195.3 | $217.5 | $(22.2) | (10.2)% |
| BSI CALID | 285.8 | 265.6 | 20.2 | 7.6% |
| BSI Nano | 252.1 | 252.5 | (0.4) | (0.2)% |
| BEST | 66.3 | 69.1 | (2.8) | (4.1)% |
| Eliminations (a) | (2.1) | (4.0) | 1.9 |  |
| &nbsp;&nbsp;Total revenue | $797.4 | $800.7 | $(3.3) | (0.4)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Represents product and service revenue between reportable segments.* 

Revenue decreases for the three months ended June 30, 2025, compared to the year ago quarter, were primarily attributable to the BSI BioSpin Segment with the decline primarily driven by weaker demand in the biopharma and industrial markets for life science instruments. This decrease was partially offset by a year-on-year increase in revenue in the BSI CALID Segment, which was primarily due to increased revenue from prior year acquisitions.

Geographically during the three months ended June 30, 2025, compared to the same period in 2024, our North American revenue decreased 8.8% and European revenue decreased by 1.2%, while Asia Pacific revenue increased by 6.8%.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Gross Profit*** 

The following table presents gross profit and gross profit margins by reportable segment for the periods reported:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** |
|  | **2025** | **2025** | **2024** | **2024** |
|  | **Gross Profit** | **Percentage of<br>Segment<br>Revenue** | **Gross Profit** | **Percentage of<br>Segment<br>Revenue** |
| BSI BioSpin | $83.4 | 42.7% | $102.7 | 47.2% |
| BSI CALID | 145.3 | 50.8% | 143.0 | 53.8% |
| BSI Nano | 115.9 | 46.0% | 121.5 | 48.1% |
| BEST | 13.3 | 20.1% | 17.4 | 25.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total gross profit | $357.9 | 44.9% | $384.6 | 48.0% |

---

The decrease in gross profit and gross profit margin, compared to the prior year quarter, were driven primarily by changes in sales mix, combined with increased cost of goods sold due to higher U.S. tariffs and foreign exchange headwinds from a declining U.S. dollar

***Selling, General and Administrative*** 

Our selling, general and administrative expenses for the three months ended June 30, 2025, increased to 29.0% of total revenue, from 27.6% of total revenue for the comparable period in 2024. The increase as a percentage of revenue was a result of increased spending related to the impact from acquisitions that occurred early in the second quarter of 2024.

***Research and Development*** 

Our research and development expenses for the three months ended June 30, 2025 increased to 12.6% of total revenue from 11.5% of total revenue for the comparable period in 2024. The increase as a percentage of revenue is a result of the current year impact of prior year acquisitions.

***Other Charges, Net*** 

Other charges, net for the three months ended June 30, 2025, decreased to $14.4 million compared to $23.0 million for the three months ended June 30, 2024. The year over year decrease was primarily attributed to lower acquisition-related expenses as fewer acquisitions closed in the second quarter of the current year compared to the comparable period in 2024. This decrease was offset by a slight increase in restructuring charges related primarily to restructuring programs as described in *Note 10, Restructuring.* Refer to *Note 9*, *Other Charges, net* for more details on our other charges, net costs. In addition, in the second quarter of 2025, the Company initiated a corporate-wide restructuring program to be implemented across multiple functions and geographies to address challenges in the current business environment. We anticipate additional restructuring charges in the third and fourth quarter of 2025 with activities under these plans expected to be completed by 2026.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Operating Income*** 

The following table presents operating income and operating margins on revenue by reportable segment for the periods reported:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** |
|  | **2025** | **2025** | **2024** | **2024** |
|  | **Operating<br>(loss) Income** | **Percentage of<br>Segment<br>Revenue** | **Operating<br>(loss) Income** | **Percentage of<br>Segment<br>Revenue** |
| BSI BioSpin | $18.1 | 9.3% | $37.3 | 17.1% |
| BSI CALID | 26.2 | 9.2% | 35.5 | 13.4% |
| BSI Nano | (13.4) | (5.3)% | (3.6) | (1.4)% |
| BEST | 7.2 | 10.9% | 10.5 | 15.2% |
| Corporate, eliminations and other (a) | (26.2) |  | (31.6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating income | $11.9 | 1.5% | $48.1 | 6.0% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Represents corporate costs and eliminations not allocated to the reportable segments.* 

The decrease in operating income and operating income margin was driven by the factors described above. In August 2025, the Company announced a significantly expanded cost savings initiative that is expected to reduce our annual costs by approximately $100 million to $120 million in 2026. These major cost reductions affect all parts of the Company's business, from supply chain and manufacturing to commercial, administrative and research and development investments. See *Note 10, Restructuring* in the Notes to Unaudited Condensed Consolidated Financial Statements.

***Interest and Other Income (Expense), Net*** 

The increase in interest and other income (expense), net in the three months ended June 30, 2025, as compared to the same period in 2024 was primarily due to lower foreign exchange differences on the revaluation of monetary items and the inclusion of a significant impairment of minority investments in the comparative prior period.

***Income Tax Provision*** 

The effective tax rate for the three months ended June 30, 2025, was not meaningful due to one-time favorable discrete events recorded during the period. The effective tax rate for the three months ended June 30, 2024 was 67.4%.

The OECD introduced its Pillar 2, which provides guidance for a global minimum tax. Various countries have either enacted or are in the process of enacting legislation to implement this framework. Our income tax provision for the three months ended June 30, 2025, reflects currently enacted legislation and guidance related to the model rules. This enacted legislation and guidance had an impact on our income tax provision, resulting in an increase to our adjusted effective tax rate of 2.3% for the three months ended June 30, 2025. We continue to monitor the countries in which it operates as they enact legislation implementing Pillar 2.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**RESULTS OF OPERATIONS** 

*Six Months Ended June 30, 2025, compared to the Six Months Ended June 30, 2024* 

***Consolidated Results*** 

The following table presents our results for the periods reports:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Six Months Ended June 30,** | **Six Months Ended June 30,** |  |  |
|  | **2025** | **2024** | **Dollar<br>Change** | **Percentage<br>Change** |
| Product revenue | $1278.0 | $1241.3 | $36.7 | 3.0% |
| Service and other revenue | 320.8 | 281.1 | 39.7 | 14.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 1598.8 | 1522.4 | 76.4 | 5.0% |
| Cost of product revenue | 668.4 | 617.7 | 50.7 | 8.2% |
| Cost of service and other revenue | 181.3 | 167.3 | 14.0 | 8.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue | 849.7 | 785.0 | 64.7 | 8.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 749.1 | 737.4 | 11.7 | 1.6% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 456.8 | 416.6 | 40.2 | 9.6% |
| Research and development | 197.3 | 174.0 | 23.3 | 13.4% |
| Other charges, net | 51.3 | 33.9 | 17.4 | 51.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 705.4 | 624.5 | 80.9 | 13.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 43.7 | 112.9 | (69.2) | (61.3)% |
| Interest and other income (expense), net | (18.1) | (17.4) | (0.7) | 4.0% |
| Income before income taxes, equity in income of<br> unconsolidated investees, net of tax, and noncontrolling <br> interests in consolidated subsidiaries | 25.6 | 95.5 | (69.9) | (73.2)% |
| Income tax provision (benefit) | 5.6 | 35.9 | (30.3) | (84.4)% |
| Equity in income (loss) of unconsolidated investees, net of tax | 1.0 |  | 1.0 |  |
| Consolidated net income | 21.0 | 59.6 | (38.6) | (64.8)% |
| Net income (loss) attributable to noncontrolling interests in <br> consolidated subsidiaries | (4.0) | 1.1 | (5.1) | (463.6)% |
| Net income attributable to Bruker Corporation | $25.0 | $58.5 | $(33.5) | (57.3)% |

---

***Revenue*** 

The following table presents revenue, change in revenue, and revenue growth by reportable segment for the periods reported:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |  |  |
|  | **2025** | **2024** | **Dollar<br>Change** | **Percentage<br>Change** |
| BSI BioSpin | $403.1 | $400.3 | $2.8 | 0.7% |
| BSI CALID | 565.9 | 493.5 | 72.4 | 14.7% |
| BSI Nano | 508.7 | 492.9 | 15.8 | 3.2% |
| BEST | 125.6 | 142.2 | (16.6) | (11.7)% |
| Eliminations (a) | (4.5) | (6.5) | 2.0 |  |
| &nbsp;&nbsp;Total revenue | $1598.8 | $1522.4 | $76.4 | 5.0% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Represents product and service revenue between reportable segments.*

Revenue increases in the six months ended June 30, 2025, compared to the year ago quarter, were driven mostly by ELITechGroup and NanoString, partially offset by organic revenue decline. The BSI CALID Segment increase in revenue was primarily from the ELITech molecular diagnostics business, which was acquired in the second quarter of 2024. BSI Nano Segment increase in revenue was primarily driven by the Nanostring business, which was acquired in the second quarter of 2024. The BEST revenue decrease was driven mainly by a softness in the clinical MRI market, as well as a strong prior-year comparison for the Research Instruments business.

------

[**<u>**Table of Contents**</u>**](#toc_page)

Geographically in the six months ended June 30, 2025, our North American revenue decreased 0.3%, Asia Pacific revenue increased by 5.7%, and European revenue increased by 7.1% driven by driven by tailwinds from acquisitions compared to the same period in 2024.

***Gross Profit*** 

The following table presents gross profit and gross profit margins by reportable segment for the periods reported:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2025** | **2024** | **2024** |
|  | **Gross Profit** | **Percentage of<br>Segment<br>Revenue** | **Gross Profit** | **Percentage of<br>Segment<br>Revenue** |
| BSI BioSpin | $177.1 | 43.9% | $194.7 | 48.6% |
| BSI CALID | 298.7 | 52.8% | 272.8 | 55.3% |
| BSI Nano | 247.3 | 48.6% | 237.3 | 48.1% |
| BEST | 26.0 | 20.7% | 32.6 | 22.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total gross profit | $749.1 | 46.9% | $737.4 | 48.4% |

---

The slight increase in gross profit compared to the prior year was driven primarily by the impact of the ELITechGroup and NanoString acquisitions that occurred in 2024 offset by associated business combination amortization expenses, combined with increased cost of goods sold due to higher U.S. tariffs and foreign exchange headwinds from a declining U.S. dollar.

***Selling, General and Administrative*** 

Our selling, general and administrative expenses for the six months ended June 30, 2025, increased to 28.6% of total revenue, from 27.4% of total revenue for the comparable period in 2024. The increase as a percentage of revenue was a result of increased costs from recent acquisitions compared to the same period in 2024.

***Research and Development*** 

Our research and development expenses for the six months ended June 30, 2025, increased to 12.3% of total revenue from 11.4% of total revenue for the comparable period in 2024. The increase as a percentage of revenue is a result of our increased research and development related costs from prior year acquisitions.

***Other Charges, Net*** 

Other charges, net for the six months ended June 30, 2025, increased to $51.3 million compared to $33.9 million for the comparable period in 2024. The year over year increase was primarily due to $22.6 million of acquisition-related litigation charges that primarily relate to the acquisitions of BCA and NanoString, $10.5 million of restructuring charges related primarily to restructuring programs as described in *Note 10, Restructuring,* offset by a decrease of $12.6 million in acquisition-related expenses due to fewer acquisitions closed in the current year compared to 2024. Refer to *Note 9*, *Other Charges, net* for more details on our other charges, net costs. In addition, in the second quarter of 2025, the Company initiated a corporate-wide restructuring program to be implemented across multiple functions and geographies to address challenges in the current business environment. We anticipate additional restructuring charges in the third and fourth quarter of 2025 with activities under these plans expected to be completed by 2026.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Operating Income*** 

The following table presents operating income and operating margins on revenue by reportable segment for the periods reported:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2025** | **2024** | **2024** |
|  | **Operating<br>Income (Loss)** | **Percentage of<br>Segment<br>Revenue** | **Operating<br>Income (Loss)** | **Percentage of<br>Segment<br>Revenue** |
| BSI BioSpin | $41.7 | 10.3% | $68.5 | 17.1% |
| BSI CALID | 66.4 | 11.7% | 76.6 | 15.5% |
| BSI Nano | (20.4) | (4.0)% | 7.2 | 1.5% |
| BEST | 14.1 | 11.2% | 18.6 | 13.1% |
| Corporate, eliminations and other (a) | (58.1) |  | (58.0) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating income | $43.7 | 2.7% | $112.9 | 7.4% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Represents corporate costs and eliminations not allocated to the reportable segments*

The decrease in operating income observed in all segments was due to factors described above.

In August 2025, the Company announced a significantly expanded cost savings initiative that is expected to reduce our annual costs by $100 million to $120 million in 2026. These major cost reductions affect all parts of the Company's business, from supply chain and manufacturing to commercial, administrative and research and development investments.

***Interest and Other Income (Expense), Net*** 

Interest and other income (expense), net in the six months ended June 30, 2025, is comparable to that in the six months ended June 30, 2024.

***Income Tax Provision*** 

The effective tax rates for the six months ended June 30, 2025, and 2024 were 21.9% and 37.6%, respectively. The decrease in the Company's effective tax rate was primarily due to a change in jurisdictional mix, and net favorable discrete activities.

The OECD introduced its Pillar 2, which provides guidance for a global minimum tax. Various countries have either enacted or are in the process of enacting legislation to implement this framework. Our income tax provision for the six months ended June 30, 2025, reflects currently enacted legislation and guidance related to the model rules. This enacted legislation and guidance had an impact on our income tax provision, resulting in an increase to our adjusted effective tax rate of 2.3% for the six months ended June 30, 2025. We continue to monitor the countries in which it operates as they enact legislation implementing Pillar 2.

**LIQUIDITY AND CAPITAL RESOURCES** 

***Cash flows***

We anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months. Our future cash requirements could be affected by acquisitions that we may complete, purchases of our common stock, or the payment of dividends in the future. Historically, we have used the liquidity generated from cash flow from operations, debt financings, and issuances of common stock to finance our growth and operating needs. In the future, there are no assurances that we will continue to generate cash flow from operations, that additional financing alternatives will be available to us, if required, or, if available, will be obtained on terms favorable to us.

We aggregate all bank accounts that are subject to our notional cash pooling arrangement into a single balance on our consolidated balance sheets. Our notional cash pooling arrangement is managed by a third-party financial institution and as of June 30, 2025, it was in a positive position. The cash and cash equivalent balance held outside of the United States in our foreign subsidiaries was primarily located in the Netherlands, Switzerland, and Hong Kong.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The following table presents our cash flows from operating activities, investing activities, and financing activities for the periods reported:

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** |
| Net cash provided by (used in) operating activities | $(62.5) | $22.9 |
| Net cash used in investing activities | (117.2) | (1629.1) |
| Net cash provided by financing activities | 44.3 | 1307.5 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 44.9 | (19.7) |
| Net decrease in cash, cash equivalents, and restricted cash | $(90.5) | $(318.4) |

---

Net cash used in operating activities during the six months ended June 30, 2025, resulted primarily from a change in operating assets and liabilities, net of acquisitions of $151.0 million, offset by consolidated net income adjusted for non-cash items of $88.5 million. Net cash provided by operating activities during the six months ended June 30, 2024, resulted primarily from consolidated net income adjusted for non-cash items of $144.7 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $121.8 million.

The decrease in consolidated net income adjusted for non-cash items was primarily due to lower income as result of increased costs related to recent acquisitions combined with negative impact of new global trade tariffs. The change in operating assets and liabilities, net of acquisitions increased primarily due to timing of income taxes payable offset by increased collections of receivables.

Net cash used in investing activities during the six months ended June 30, 2025, resulted primarily from cash paid for acquisitions of $69.5 million, purchases of property, plant and equipment of $47.3 million, and minority investments of $3.2 million. Net cash used in investing activities during the six months ended June 30, 2024, resulted primarily from cash paid for acquisitions of $1,576.5 million, purchases of property, plant and equipment of $46.0 million, and minority investments of $10.0 million, offset by $2.5 million of proceeds from cross-currency swap agreements.

Net cash provided by financing activities during the six months ended June 30, 2025, was primarily from net proceeds of our revolving line of credit of $89.1 million, proceeds from long-term debt of $2.9 million, offset by repayments of long-term debt of $22.3 million, the payment of dividends to common shareholders of $15.3 million, and cash paid for purchases of common stock under our repurchase program of $10.0 million. Net cash provided by financing activities during the six months ended June 30, 2024, was primarily from net proceeds from our revolving line of credit of $233.2 million, proceeds from long-term debt of $805.7 million, proceeds from our public offering of common stock $402.9 million, offset by the repayment of our 2012 Note Purchase Agreement of $100.0 million, and the payment of dividends to common shareholders of $15.0 million.

***Share Repurchase Program*** 

Refer to *Note 21, Shareholder's Equity,* in the Notes to our Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for more information on our share repurchase program.

***Incentive Compensation Plan***

In May 2025, the 2026 Plan was approved by our stockholders. The 2026 Plan will be effective as of the Effective Date, which will be the date immediately following the date on which the Prior Plan expires. No additional awards will be granted under the Prior Plan on or after the Effective Date. The 2026 Plan provides for the issuance of up to 12,000,000 shares of our common stock. The 2026 Plan, will be administered by the Compensation Committee of the Board or another Committee, and provides for grants of awards to non-employee directors, employees, and certain of our key advisors in the form of nonqualified and incentive options, stock awards, stock units, stock appreciation rights, cash-based awards, and other awards. The Committee has the authority to determine which employees will receive awards, the amount of any awards, and other terms and conditions of such awards. The 2026 Plan will terminate on May 28, 2035, unless terminated earlier pursuant to its terms.

***Credit Facilities*** 

As of June 30, 2025, we have total outstanding debt of $2.4 billion and a revolving credit facility that provides for up to $900.0 million of backup liquidity to finance working capital needs, refinance or reduce existing indebtedness, and for general corporate use. In addition, the facility provides for an uncommitted incremental facility whereby, under certain circumstances, we may, at our option, increase the amount of the revolving facility or incur term loans in an aggregate amount not to exceed $400 million. As of June 30, 2025, we were in compliance with all covenants of our debt agreements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

For a summary of the fair and carrying values of our outstanding debt as of June 30, 2025, and December 31, 2024, refer to *Note 15, Debt and Note 16, Fair Value of Financial Instruments* to our unaudited condensed consolidated financial statements included in this report. For additional information on our outstanding debt and credit facility refer to, *Note 21, Debt*, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES** 

There have been no material changes to our critical accounting policies and estimates since December 31, 2024. Refer to our Annual Report on Form 10-K for the year ended December 31, 2024 for a discussion of our critical accounting policies.

**RECENT ACCOUNTING PRONOUNCEMENTS** 

Information regarding recent accounting standard changes and developments is incorporated by reference from Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this document and should be considered an integral part of this Item 2. Refer to *Note 2, Recent Accounting Pronouncements* in the Notes to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for recently adopted and issued accounting standards.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK** 

Information concerning market risk is contained in Item 7A "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report on Form 10-K for the year ended December 31, 2024. As of June 30, 2025, there were no material changes in our exposure to market risk from December 31, 2024 other than the following:

**Tariff Risks** 

During the second quarter of 2025, various tariffs were announced and modified on imports into the U.S. The universal baseline tariff of 10% announced April 2, 2025 remained in place for most trading partners, and significant additional country-specific rates were announced August 1, 2025 to become effective August 7, 2025 (or October 5, 2025 for goods loaded on board a vessel before that date) pending negotiation of trade agreements providing for a lower rate. The U.S. Government has imposed 50% tariffs on designated steel, aluminum, and copper imports following industry-specific considerations, and additional tariffs may be imposed on imported semiconductors, processed critical minerals, and other industries in the future, as U.S. government considerations of those industries remains ongoing. The imposition of these tariffs has impacted our profitability to the extent that we have not been able to pass along the impact to our customers. We are continuing to assess how the increased tariffs, including potential reciprocal tariffs, may affect operating profitability, business operations, and strategies to mitigate potential cost increases.

**ITEM 4. CONTROLS AND PROCEDURES** 

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) by others within our organization. Under the supervision and with the participation of our management, including our Chief Executive Officer, and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2025. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2025.

Management concluded that the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q fairly state, in all material respects, our financial condition, results of operations, and cash flows for the periods presented in conformity with GAAP.

**Changes in Internal Controls over Financial Reporting** 

There have been no changes in our internal control over financial reporting during the three months ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PART II OTHER INFORMATION** 

**ITEM 1. LEGAL PROCEEDINGS** 

We are involved in lawsuits, claims, and proceedings, including, but not limited to, patent, customer, labor and employment, and commercial matters, which arise in the ordinary course of business. As of June 30, 2025, other than as disclosed in *Note 20, Commitments and Contingencies* in the Notes to our Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q, the Company is not party to any material pending legal proceedings other than ordinary routine litigation incidental to the Company's business, to which the Company or any of its subsidiaries is a party or of which any of their property is the subject. However, the outcome of any of these proceedings cannot be accurately predicted, and the ultimate resolution of any of these existing matters may have a material adverse effect on the Company's business or financial condition.

In addition, we are subject to regulations by national, state and local government agencies in the United States and other countries in which we operate. From time to time, we are the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties, and administrative remedies which could have a material adverse effect on our financial position, results of operations and/or liquidity.

**ITEM IA. RISK FACTORS** 

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS** 

Pursuant to a share repurchase program approved by the Board of Directors and announced on May 12, 2023 (the "2023 Repurchase Program"), the Company was permitted to purchase up to $500.0 million of shares of its common stock over a two-year period. Authorization to purchase shares under the 2023 Repurchase Program expired in May 2025. The Company did not make any purchases of its common stock during the quarter ended June 30, 2025.

**ITEM 5. OTHER INFORMATION**

***Director and Officer Trading Arrangements***

During the quarter ended June 30, 2025, none of the Company's directors or officers informed the Company of the adoption or termination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement", as those terms are defined in Regulation S-K, Item 408, except as follows:

On April 23, 2025, Dr. Cynthia Friend, a member of the Company's Board of Directors, terminated a trading plan she had previously adopted with respect to the sale of securities of the Company's common stock, intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act ("Rule 10b5-1 Trading Plan"). Dr. Friend's Rule 10b5-1 Trading Plan was adopted on February 18, 2025, and provided for the sale of up to (a) 5,192 shares of the Company's Common Stock underlying time-based restricted stock units and (b) 4,300 shares of Common Stock underlying stock options granted under an equity compensation plan. As of the date of termination of her Rule 10b5-1 Trading Plan, Dr. Friend did not sell any shares of common stock under the terms of the Rule 10b5-1 Trading Plan.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ITEM 6. EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit No.**<br>| &nbsp;&nbsp;&nbsp;**Description**<br>|
| &nbsp;&nbsp;10.1 | &nbsp;&nbsp;&nbsp;[<u>Bruker Corporation 2026 Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, File No. 000-30833, filed May 29, 2025)</u>](https://www.sec.gov/Archives/edgar/data/1109354/000095017025079029/brkr-ex10_1.htm) |
| &nbsp;&nbsp;31.1\* | &nbsp;&nbsp;&nbsp;[<u>Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](brkr-ex31_1.htm) |
| &nbsp;&nbsp;31.2\* | &nbsp;&nbsp;&nbsp;[<u>Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](brkr-ex31_2.htm) |
| &nbsp;&nbsp;32.1\*\* | &nbsp;&nbsp;&nbsp;[<u>Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>](brkr-ex32_1.htm) |
| &nbsp;&nbsp;101.INS\* | &nbsp;&nbsp;&nbsp;Inline XBRL Instance Document — the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the inline XBRL document |
| &nbsp;&nbsp;101.SCH\* | &nbsp;&nbsp;&nbsp;Inline XBRL Taxonomy Extension Schema Document with Embedded Linkbase Documents |
| &nbsp;&nbsp;104\* | &nbsp;&nbsp;&nbsp;Cover page formatted in Inline XBRL and contained in Exhibit 101 |

---

\* Filed herewith.

\*\* Furnished herewith

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Date: August 5, 2025 | &nbsp;&nbsp;&nbsp;&nbsp;BRUKER CORPORATION | &nbsp;&nbsp;&nbsp;&nbsp;BRUKER CORPORATION |
|  | &nbsp;&nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ FRANK H. LAUKIEN, PH.D. |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Frank H. Laukien, Ph.D. |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*President, Chief Executive Officer and Chairman* |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*(Principal Executive Officer)* |
| &nbsp;&nbsp;&nbsp;&nbsp;Date: August 5, 2025 | &nbsp;&nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ GERALD N. HERMAN |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Gerald N. Herman |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*Executive Vice President and Chief Financial Officer* |
|  |  | *(Principal Financial Officer)* |
| Date: August 5, 2025 | &nbsp;&nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ THOMAS BURES |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Thomas Bures |
|  |  | *Chief Accounting Officer* |
|  |  | *(Principal Accounting Officer)* |

---

------

## Exhibit 31.1

**EXHIBIT 31.1** 

**CERTIFICATION** 

I, Frank H. Laukien, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Bruker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 5, 2025 | By: | /s/ FRANK H. LAUKIEN, PH.D. |
|  |  | Frank H. Laukien, Ph.D. |
|  |  | *President, Chief Executive Officer and Chairman* |
|  |  | *(Principal Executive Officer)* |

---

------

## Exhibit 31.2

**EXHIBIT 31.2** 

**CERTIFICATION** 

I, Gerald N. Herman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Bruker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 5, 2025 | By: | /s/ GERALD N. HERMAN |
|  |  | Gerald N. Herman |
|  |  | *Executive Vice President and Chief Financial Officer* |
|  |  | *(Principal Financial Officer)*  |

---

------

## Exhibit 32.1

**EXHIBIT 32.1** 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT** 

**TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Quarterly Report of Bruker Corporation (Company) on Form 10-Q for the three and six months ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (Report), each of the undersigned, Frank H. Laukien, President, Chief Executive Officer and Chairman of the Board of Directors of the Company, and Gerald N. Herman, Chief Financial Officer and Executive Vice President of the Company, certifies, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Date: August 5, 2025 | By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ FRANK H. LAUKIEN, PH.D. |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Frank H. Laukien, Ph.D. |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*President, Chief Executive Officer and Chairman* |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*(Principal Executive Officer)* |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Date: August 5, 2025 | By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ GERALD N. HERMAN |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Gerald N. Herman |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*Executive Vice President and Chief Financial Officer* |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*(Principal Financial Officer)*  |

---

------